Next Article in Journal
Direct Production of 2-Butanol from Glucose by Recombinant Klebsiella pneumoniae Strains
Previous Article in Journal
Chitosan- and Gelatin-Based Composite Granular Hydrogels for Cartilage Tissue Regeneration
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 27
Issue 6
10.3390/ijms27062891
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Tracheal Regeneration: Recent Progress in the Application of Stem Cells in Tracheal Bioengineering

by
Fatemeh Ganji
1,
Florian Le Billan
1,
Siba Haykal
1,2 and
Golnaz Karoubi
1,3,4,*
1
Latner Thoracic Research Laboratories, University Health Network, Toronto, ON M5G 1L7, Canada
2
Division of Plastic and Reconstructive Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT 06510, USA
3
Department of Mechanical and Industrial Engineering, University of Toronto, Toronto, ON M5S 1A1, Canada
4
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A1, Canada
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2026, 27(6), 2891; https://doi.org/10.3390/ijms27062891
Submission received: 25 February 2026 / Revised: 15 March 2026 / Accepted: 21 March 2026 / Published: 23 March 2026
(This article belongs to the Special Issue Regenerative Medicine: Biomaterials and Stem Cell Research: 2nd Edition)
Browse Figures
Versions Notes

Abstract

Traumatic injury, stenosis, and malignancy involving large segments of the airway are difficult to reconstruct and require novel solutions. Despite advances in surgical techniques, the reconstruction of long-segment tracheal defects remains a significant challenge. Several bioengineering approaches have been explored for tracheal regeneration in vitro and in vivo, using cells in combination with three dimentional (3D) biological or synthetic scaffolds. This paper reviews recent advances in developing bioengineered trachea and the technologies utilized toward generating transplantable tracheal grafts. Specifically, the review will focus on the recellularization of tissue-engineered grafts using natural or synthetic scaffolds, highlighting relevant cell types used to reconstitute tracheal epithelium and cartilage. The promise of newly explored paradigms, including the application of pluripotent stem cells, will be discussed with an overview of associated challenges and necessary steps for future translation. Overall, these advances provide a foundation for the development of clinically viable tracheal grafts, bringing engineered tracheal reconstruction closer to reality.

Graphical Abstract

1. Introduction

The trachea is a semi-flexible tube composed of 20 incomplete C-shaped outer rings of hyaline cartilage, middle connective tissue, and an inner epithelial layer [1]. The cartilage tissue provides mechanical strength, preventing tracheal collapse during breathing. The internal surface of the trachea is lined with pseudostratified mucociliary epithelium composed of multiciliated, goblet and basal cells, which serve as a barrier and help remove particles and debris from the airway [2,3]. Tracheal dysfunction is associated with damage to the epithelium and cartilage, resulting from surgical injury, tumor, infection, and prolonged intratracheal intubation. Extensive damage leads to tracheal stenosis, tracheomalacia, and airway collapse [4,5]. Despite advances in surgical techniques in recent decades, long-segment tracheal defects remain a significant challenge. To address this challenge, many research groups are exploring bioengineering approaches as an alternative technology for tracheal regeneration in vitro and in vivo, using autologous cells in combination with 3D biological or synthetic scaffolds [6]. While there is a considerable amount of literature focusing on the use of synthetic materials for tracheal graft generation [7,8], the choice of material alone is insufficient; successful grafts require functional cells to restore airway structure and function. This review will focus predominantly on the use of natural biomaterials in combination with various cell sources.
Bioengineered tracheal grafts require two main components: cartilage and the epithelium. Over the last several years, there has been significant effort put forth toward achieving a transplantable bioengineered tracheal graft. While progress has been made, research in the tracheal tissue engineering field has shown that there are considerable challenges that impede adequate cartilage and epithelial regeneration [9,10,11,12]. Perhaps one of the most critical limitations in tracheal tissue engineering is the lack of a functional epithelium. Indeed, preclinical and clinical studies demonstrated that the absence of epithelium leads to airway stenosis and obstruction, resulting in graft failure [13,14,15]. Consequently, recent research in the field has focused on the recellularization of the tissue-engineered grafts that has been shown to accelerate tissue regeneration [16,17,18,19].
Various cell types have been employed for the recellularization of tracheal grafts. These include cell lines [19,20], primary epithelial cell populations such as tracheal epithelial cells [21,22], nasal epithelial cells [11,23] and, more recently, pluripotent-derived cells [24,25]. Of particular interest are induced pluripotent stem cells (iPSCs), which have the capacity for self-renewal and differentiation—similar to that of embryonic stem cells (ESCs). These properties make them highly relevant for therapeutic applications [26,27]. IPSCs are advantageous in that they can be derived from various cell sources [28,29,30,31], lack the ethical complexities associated with ESCs, and can be patient-specific, thus evading immune rejection [32,33,34,35]. Recent advances in directed differentiation protocols toward generating airway epithelial cells have shown that iPSCs can differentiate into a mature airway epithelium composed of ciliated, goblet and basal cells [36,37,38,39,40,41], making them ideal for the recellularization of tracheal grafts. Here, we review advances in tracheal tissue engineering and focus on recent progress of the application of iPSCs in the generation of tracheal grafts.

2. Clinical Need and Current Approaches for Tracheal Repair and Replacement

Tracheal dysfunction or long-segment tracheal defects can be either congenital or secondary due to trauma, infection, or several types of cancer. An estimated 2.5 to 3.2% of trauma-associated morbidity and mortality results from tracheal injury [5]. In adults, malignant tumors in the airways cause tracheal stenosis and obstruction that require tracheal resection and reconstruction [42,43]. In intensive care unit patients or COVID-19 patients, it has been shown that prolonged endotracheal intubations cause laryngotracheal injuries and stenosis after extubation [44,45,46]. Currently, surgical techniques such as end-to-end anastomosis and surgical reconstruction of the trachea are the gold standard for the treatment of tracheal injuries in clinic but are not adequate for damage to the trachea that exceeds 50% of the tracheal length in adults and 30% of the tracheal length in children [5,47]. For long-segment defects, increased anastomotic tension and serious complications can exuberate injury [48,49]. Additionally, in circumstances in which the defect includes both the larynx and the trachea or is very close to the glottal area, end-to-end anastomosis is not ideal [50]. In these cases, the only viable treatment option is circumferential tracheal transplantation in which longer segments are reconstructed [51,52,53].
Currently, circumferential tracheal transplantation involved a two-stage surgical technique: the heterotopic/orthotopic allotransplantation. This involves placement of the donor trachea first in a highly vascularized heterotopic region of the recipient (such as the forearm) for an extensive period (weeks to months), which is followed by its subsequent transfer into an orthotopic position [54]. While tracheal allograft transplantation has been applied in the clinic and led to significant advances in treating long-segment tracheal defects [55,56], limitations remain that prevent graft functionality. These include the possible formation of fibrosis and stenosis, the induction of immune response, a lack of neovascularization, and inadequate epithelial regeneration and function in transplanted grafts [52,57,58]. Moreover, allograft transplantation requires an availability of donor tissues, is often associated with multiple surgeries, and it is also is very invasive. This significantly strains patient quality of life. Therefore, the use of naturally derived biomaterials to develop a biocompatible transplantable graft with low immunogenicity is an exciting alternative that may address some of these limitations [59,60,61,62].

3. Natural Biomaterials and Decellularized Tracheal Tissue Scaffolds for Bioengineered Grafts

Natural biomaterial-derived hydrogels are classified as protein-based (e.g., gelatin, collagen) and polysaccharide-based (e.g., agarose, alginate, starch) hydrogels [63]. Commonly used natural biomaterials in trachea regeneration include collagen, chitosan, gelatin, fibrin glue and silk fibroin. They allow the generation of porous scaffolds loaded with cells, and allowed cell growth and proliferation [64]. Table 1 summarizes reports using naturally derived biomaterials for use in tracheal regeneration. In parallel to the use of simple natural biomaterials, there have been significant efforts placed on using decellularized biological tracheal scaffolds.
Over the past decade, the decellularization of animal tracheal grafts, to generate naturally occurring acellular biological scaffolds, has received considerable attention (Figure 1). Using this approach, a biological scaffold is obtained by the full [65] or partial [11,66,67] removal of cells and cellular debris from the tissue while preserving the three-dimensional extracellular matrix (ECM) and its components. The main advantage of acellular biological scaffolds is the preservation of the microstructure of native tissue provided by the ECM along with signaling molecules, as it facilitates cell attachment, growth and differentiation [65,68]. Numerous decellularization protocols have been developed by combining physical, chemical, and/or enzymatic approaches [69]. Their common objective is to achieve the partial or complete removal of native cells while minimizing harmful effects on the ECM structure and composition [70,71,72]. And complete removal of the cells has been shown to result in damage to the tracheal tissue and a decline of mechanical strength [72,73]. To circumvent these challenges, many investigators pivoted research toward the use of recellularized grafts via repopulation of the lumen, cartilaginous layer or both [11,20,59].
Table 1. Natural biomaterials and biological scaffolds for bioengineered tracheal grafts.
Table 1. Natural biomaterials and biological scaffolds for bioengineered tracheal grafts.
Scaffold/
Material		Graft SizeCell SourceExperimental DetailsOutcomesStudy
Acellular tracheal patch allograftsPatch
15 × 15 mm		No cellsPigs (4w) were transplanted with acellular allogeneic tracheal grafts followed by
bronchoscopic and histological evaluation at 11 weeks post-transplantation.		Acellular grafts showed some re-vascularization and re-epithelialization after implantation with regeneration of cartilage foci adjacent to the grafts. However, grafts failed due to stenosis and collapse.[74,75]
Acellular and recell-
ularized tracheal allografts		Long-segment circumferential graft
2–3 cm		Autologous mesenchymal stromal cells (MSCs) and tracheal epithelial cellsPorcine acellular and recellularized long-segment circumferential tracheal allografts heterotopically transplanted and followed by evaluation of in vitro and in vivo T cell proliferation and infiltration.Acellular graft delayed leukocyte infiltration, but eventually cartilage degradation was observed due to the incomplete removal of MHC in the submucosal gland and CD4+ T cells induction. Recellularization induced immunological tolerance by the recruitment of CD4+CD25+Foxp3+ regulatory T cells. [59]
Partially decellularized acellular
trachea		Long-segment graft
3–4 mm		No cellsHeterotopic transplant of mice acellular trachea was evaluated at 28 days post-implantation. Restoration of the tracheal micro-
vasculature was quantified by counting CD31+ cells within the submucosa. Graft
patency was assessed in vivo with micro-computed tomography.		Implantation of partial acellular grafts resulted in the restoration of native tracheal rigidity, high chondrocyte viability, neo-epithelialization and endothelialization at endpoint.[60]
Acellular tracheal
allografts		Long-segment graft
5 × 5 mm		Canine tracheal epithelial cells and canine yolk sac endothelial progenitor cells (YS)Recellularized canine trachea scaffolds
fragments were implanted subcutaneously into the right and left medial dorsal
thoracic region of nude mice. Control
group received acellular scaffold. 		Implanted tissue remained preserved and proliferative, and no fibrotic tissue process was observed in animals after 45 days.
Differentiation ability was shown through the CK18 and β-tubulin expression in epithelial cells. 		[22]
Combination of
acellular tracheal
and acellular hum-
an dermis		Long-segment graft
5 cm		Human bronchial epithelial cells (HBECs) and lung fibroblastsTissue-engineered respiratory mucosa was generated via recellularization of human dermis (HBECs and lung fibroblasts) in air liquid interface (ALI) culture system and subsequently engrafted on pre-vascula-rized, acellularized trachea and hetero-
topically implanted into immunosuppressed rabbits and nude mice.		Integration of graft with sign of re-vascularization was observed as well as infiltration of inflammatory cell. In vivo experiment demonstrated survival and retention of epithelial cells that expressed pan-keratin.[61]
Acellular tracheal graftFully circumferential graft
5–7 rings length		Mouse iPSC-derived definitive endoderm cellsRecellularized rat tracheal segments (7 rings) were orthotopically transplanted on nude rats.Luminal surface of graft re-epithelialized with numerous ciliated epithelial cells. Animals died after 5 weeks due to airway stenosis.[20]
Partially decellularized autograftPatch
1 × 1 cm 		Autologous nasal epithelial cell sheetCell sheets were prepared via seeding porous polyethylene terephthalate (PET)
membranes. Defects were made via
removal of epithelium in situ. Sheets were applied onto the luminal surface of the
decellularized graft immediately re-transplanted into the original defect. Control group was transplanted with decellula-rized trachea without cell sheet
application.		At two months post-operation, orthotopic transplantation of graft indicated integration of graft into the host trachea with healing of luminal surface. In control groups, epithelial hypertrophy, fibroproliferation and neovascularization in sub-epithelial layer was observed.[11]
Partially decellularized tracheal scaff-
old (porcine trachea)		Circumferential tracheal graft (~5 cm)No cells Partially decellularized tracheal segments were implanted in a porcine model and evaluated by bronchoscopy, imaging, and histology at day 28 and day 56 post-
implantation to assess biointegration.		The scaffold showed progressive biointegration with neovascularization, fibroblast colonization of the scaffold, no infection or tissue necrosis and no significant graft rejection at day 28. However, cartilage regeneration remained limited and structural integrity was not fully restored at day 56[76]
Polypropylene mesh and collagen spongePatch
12 mm in diameter		Mouse iPSCs-derived epithelial cells5-day-old iPSCs-derived embryoid bodies (EBs) were cultured at ALI model for 28 days. EBs containing ciliated-like structures were loaded on collagen-coated artificial tracheal graft followed by orthotopic transplantation into nude rats.Effective coverage of artificial material with differentiated epithelium with γ-tubulin expression on the basal sides of ciliated cells after 7 days. Only 50% of nude rats used for the experiment showed iPSCs-derived tissues.[77]
Collagen, polypropylene mesh and
collagen vitrigel membrane		Patch
12 mm in diameter 		Human iPSC-derived multiciliated airway cells (MCACs)42-day-old proximal airway progenitor
cells were cultured on collagen vitrigel membrane under ALI condition to create cell sheet. Internal side of an artificial trachea consisting of polypropylene mesh
and collagen sponge was covered by
hiPSC-MCACs sheet and transplanted
into a nude rat trachea. 		The survival of transplanted cells in the endotracheal epithelium of tracheal defect was observed at 1 and 2 weeks after transplantation and hiPSC—MCACs displayed motile cilia on collagen vitrigel membrane.[24]
Silk fibroin and collagen vitrigel membrane (SF-CVM)Patch
2.5 cm in diameter 		Human iPSC-derived airway epithelial cellsFabricated SF-CVM was glued onto trans-well inserts using fibrin glue, rehydrated and seeded with airway progenitors.
Subsequent culture in ALI achieved functional mucociliary epithelia. hiPSC-derived SF-CVM grafts were evaluated in ex vivo and in porcine tracheal defects.		Differentiation of mucociliary epithelium was achieved on SF-CVM graft after 3 days. Integration with host tracheal tissue was observed as well as no airway collapse. SF-CVM graft was covered with hiPSC-derived p.seudostratified epithelium (~80%) on day 3 with reduction in granulation tissue formation.[25]
Core–shell poly (L-lactic acid-co-Ɛ-caprolactone)/collagen scaffolds containing TGF-β3Patch
1 × 2 cm		Rabbit mesenchymal stromal cells (MSCs)Electrospun PLCL–collagen membrane
with a ratio of 75:25 containing TGF-β3
was spread on 6 3D-printed grooved
PLCL molds (6 mm diameter) each seed-ed with cells. Molds were stacked and cultured for 7 days and then implanted into rabbit tracheal defects. 		Sustained release of TGF-b3 scaffolds induced the differentiation of chondrogenic cells. Tracheal integrity was maintained for 2 months after restoration; meanwhile, the entire luminal surface of the engineered patch was re-epithelialized. [78]
Porcine atelocoll-
agen (I and III) sponge and poly
propylene framework		Patch tracheal defect size (2 mm wide, over two cartilages)Autologous adipose tissue-derived stem cells (ASCs)Collagen sponge containing polypropylene mesh was prepared and used as tracheal graft. The collagen solution containing ASCs was stratified on the tracheal graft and then incubated for 1 h to form a collagen gel. Stratified trachea graft was transplanted into porcine tracheal defect.ASC transplantation after 3 weeks promoted ciliogenesis with ciliary function comparable to the normal rat trachea.[62]
Polycaprolactone (PCL) and hydrogelSemi-circumferential
1.5 × 1.5 cm		Autologous nasal epithelial cells and chondrocyte cellsArtificial trachea (5 layers consisting of
PCL, alginate with epithelial cells, PCL,
alginate with chondrocytes and PCL).
Grafts transplanted into rabbit tracheal
defect for graft without cells used as a
control.		Observation at 3, 6 and 12 months showed that artificial tracheas were effective in the regeneration of respiratory epithelium but not in cartilage regeneration.[79]
3D-printed polycaprolactone (PCL) backbone integrated with freeze-dried
collagen–hyaluronic acid (CHyA) layer		Tubular scaffold
Inner diameter: 9.6 mm
Outer diameter: 12 mm		Calu-3 respiratory epithelial cells and Wi38 lung fibroblastsScaffolds were fabricated using a 3D-printed PCL framework reinforced with a CHyA layer. Hybrid scaffolds facilitated spatially targeted seeding of epithelial
cells on the luminal surface and fibroblasts on the outer layer.		PCL reinforcement significantly improved scaffold mechanical stability. Targeted seeding enabled spatial cell organization, resulting in successful epithelial coverage and sustained fibroblast viability, demonstrating a promising platform for tracheal tissue engineering.[80]

4. Recellularization of Acellular Tracheal Grafts

The objective of recellularization is to recreate the microanatomy of the tissue and/or organ with the ultimate goal of creating a functional bioengineered graft. Recellularization requires the use of appropriate cell sources, effective seeding methods, and physiologically relevant cell culture methods usually carried out in customized bioreactor systems. In the case of the trachea, several bioreactor systems allow decellularization and/or recellularization [18,19,81,82]. Studies, including ours [59], have found that recellularization results in improved graft outcomes following transplantation [15,18,22]. In addition, ex vivo experiments have demonstrated that the resulting epithelium provides cues for the promotion of vascularization and angiogenesis [83,84].
There have been several cell sources used for the recellularization of tracheal grafts with the objective to reconstitute the epithelium and the cartilage (Table 2). Fully differentiated somatic cell types include chondrocytes [85,86,87,88,89,90] and epithelial cells [21,91,92,93]. Progenitor cell populations, that display greater plasticity, include subtypes of adult mesenchymal stem cells (bone marrow, adipose, umbilical cord blood and amniotic fluid-derived mesenchymal stem cells (MSCs)) [59,78,94,95,96,97,98]. More recently, iPSCs have been investigated as a cell source. These include iPSC-derived mesenchymal stem cells (iPSC-MSCs), iPSC-MSC-derived chondrocytes [99,100,101,102] and iPSC-derived epithelial cells [77,103]. These cells have the added advantage of allowing patient specificity for personalized bioengineered grafts [32,39,104,105,106,107,108]. Table 2 summarizes the different cell sources used for tracheal graft recellularization; we will discuss cell sources with a specific focus on the use of pluripotent stem cells.
Table 2. Cell sources for tracheal tissue engineering.
Table 2. Cell sources for tracheal tissue engineering.
Cell TypeTissue SourceAdvantagesLimitationsStudy
ChondrocytesAuricularEasily accessible Limited purity and yield
Limited expansion in culture
Limited survival in vivo


Difficult to harvest with limited yield and lower proliferation capacity 		[86,109,110]
Nasal septum cartilagePhenotypically and functionally similar to tracheal chondrocytes[88,111,112,113]
Costal cartilage[88]
Tracheal cartilageIdeal biomimicry[87,112]
Mesenchymal stromal cellsBone marrow-derived MSCs (BMSCs)Good capacity to differentiate into chondrogenic lineages Decreased proliferative and multipotent capacity with increasing donor age

Can be differentiated to hyaline cartilage-like tissue derived from MSC. Limited capacity to keep phenotype and function

Tendency of MSC to differentiate toward hypertrophic cartilage instead of hyaline cartilage

MSC-derived chondrocytes upregulate type II collagen, proteoglycans and upregulation hypertrophy markers, such as type X collagen, and alkaline phosphatase 		[114]
Adipose-derived MSCs (AMSCs)Easier to harvest and expand in vitro compared with BMSCs, and have multi-differentiation potential that is independent of age[115]
Umbilical cord blood-derived MSCs (UCB-MSCs)Good capacity to expand and differentiate[96,116]
Amniotic fluid-derived MSCs (AFMSCs)AFMSCs are able to differentiate into lineages of three germ layers and have no tumorigenicity in vivo unlike ES cells[117,118]
Epithelial cellsTracheal epithelial cellsIdeal biomimicry Difficult to harvest in large numbers

Limited proliferation and differentiation		[18,21,91]
SMG-associated myoepithelial cellsCapacity to differentiate and reconstitute tracheal epithelium
Nasal turbinate epithelial cellsSimilarities to tracheal epithelium
Can be expanded in culture
Skin epithelial cellsHave capacity to transdifferentiate into tracheal epithelial cells and chondrocytes
Skin epithelial cells are easily accessible and can be expanded to large numbers		[119]
Epithelial stem cellsEndogenous stem/progenitor cells present in the respiratory tract, such as ductal cells, basal cells and variant club cellsAble to differentiate into different types of tracheal epithelial cells
No risk of tumor formation		Challenging to isolate and culture[120]
ESCsPluripotent ES cells derived from the inner cell mass of the blastocystES cells could generate a fully differentiated airway epithelium composed of basal, ciliated, intermediate and club cells Ethical issues with ESCs given their source

Immune rejection resulting from ESCs

Differentiated cells derived from ESCs and iPSCs are often heterogeneous and purity is variable
Risks of tumor formation in vivo		[121,122,123]
iPSCsDerived from somatic cells which can be patient specificCapable of differentiation into a variety of cell lineages
Non-immunogenic cells
No ethical issues		[20,24,25,77,100,101,124,125]

5. Recellularization Approaches for Cartilage Regeneration

Tracheal cartilage is a highly organized tissue in which complex structural extracellular networks enclose chondroblasts and chondrocytes [126]. Cells sparsely populate the tissue, which is otherwise composed of highly cross-linked extracellular matrix (10% aggrecan, 75% water, and a mix of collagen fiber and other constituents).
Primary chondrocytes are limited in their proliferative capacity and are prone to rapid changes in their phenotype in culture [127,128]. MSCs are the most commonly used cell type for recellularization of the tracheal cartilage, as they are easily accessible and expandable, and they display low immunogenic properties [129,130]. In addition, they produce a wide range of trophic and immunomodulatory factors [129,131], which enhance their therapeutic potential [101,132,133]. However, there are several disadvantages associated with the recellularization of grafts with MSCs. These include significant variability in their characteristics, and function in long-term culture [133,134,135]. In addition, grafts recellularized with MSCs do not fully recapitulate the mechanical properties of the native trachea [16,136].

6. Use of PSCs for Cartilage Regeneration

iPSCs have recently been explored as a source from which chondrocytes can be derived [137,138,139,140]. Pluripotent stem cells can be differentiated into chondrocytes as a monolayer when cultured in the presence of specific growth factors. For chondrogenesis via monolayer culture, after 1 week of culture in a pro-mesodermal medium (supplemented in BMP-4, PDGF-BB and FGF2), culture media is replaced with basic culture media supplemented in TGF-β3 for a subsequent week and with both TGF-β3 and IGF-1 for another week [141]. Other protocols involve the generation of embryoid bodies from ESCs or iPSCs, which give rise to mesenchymal stromal cell (MSC) outgrowths. MSCs are then selected via cell sorting and committed to a chondrocyte lineage using TGF-β3. Chondrocytes are evaluated by the expression of phenotypic markers type II collagen, aggrecan and Sox9 [142].
In 2010, Imaizumi et al. reported the first application of iPSC-derived chondrocytes for the repair of a tracheal cartilage defect (Figure 2) [100]. Mouse iPSCs were seeded on collagen sponge/polypropylene mesh and differentiated for 6 weeks into chondrocytes. The mesh was then transplanted into tracheal defects (1.5 mm wide, 2.5 mm long) in a nude rat model. In vivo analysis at four weeks post-transplantation showed that a tenth of the original defect displayed the formation of cartilage-like tissue in two out of four rats. However, the regenerated tissue was relatively far from the defect area. Importantly, all transplanted rats revealed teratoma formation due to the presence of undifferentiated iPS cells. Limited regeneration was thought to be due to the poor differentiation of iPSCs into chondrocytes. A subsequent study from this group further characterized the differentiation of iPSC into chondrocytes at different time points both in vivo and ex vivo after transplantation in rats (Figure 2) [124]. Ex vivo assessment showed the expression of chondrocyte markers type II collagen and aggrecan at four weeks and S-100 protein at six weeks. The effects of the duration of iPSC differentiation into chondrocytes on cartilage formation were evaluated ex vivo one week or four weeks after transplantation. Results showed no cartilage formation in the animals transplanted with the three-week differentiated iPSCs. While in those transplanted with the six-week differentiated iPSCs, the positive expression of type II collagen, indicating cartilage regeneration, was observed in all recipients at one week after transplantation. However, at four weeks post-transplantation, only three out of eight rats showed cartilage formation within the edge of the scaffolds. The authors suggested that differentiated iPSCs might dedifferentiate or die in vivo over time. Despite areas of cartilage regeneration, results also showed teratoma formation in fourteen out of eighteen rats. The most recent study from the Omori group investigated the use of hiPSCs-derived MSCs, grown on their signature patch made of collagen sponge and polypropylene mesh, to regenerate cartilage. Twelve weeks after their transplantation into tracheal defects, three out of seven nude rats exhibited cartilage-like tissue generation [143].
Kim et al. reported the use of iPSC-derived MSCs and chondrocytes for the fabrication and transplantation of a double-layer tubular scaffold in a rabbit tracheal defect model (Figure 2) [101]. The tubular construct was composed of an inner layer of electrospun PCL nanofibers and an outer layer of 3D-printed PCL microfibers. Both layers were coated with matrigel to enhance cell attachment. Human bronchial epithelial cells (hBECs) were used to cover the inner layer, and human iPSC-derived mesenchymal stem cells (hiPSC-MSCs) or human iPSC-MSC-derived chondrocytes (iPSC-Chds) were seeded onto the outer layer. Constructs were transplanted in a rabbit segmental tracheal defect (1.5 cm long) and evaluated at four weeks post-transplantation. Hematoxylin and eosin (H&E) staining, safranin O staining results and micro-CT images revealed that groups receiving iPSC-Chds, and to a lesser extent iPSC-MSCs, were effective in cartilage formation compared to the acellular scaffold controls. Moreover, they found a significant decrease in mononuclear cells in the iPSC-MSC and iPSC-Chd groups compared with the control groups. The newly formed cartilage spread well along the 3D-printed mesh structure, especially in the iPSC-Chd group. Both experimental groups were also effective in supporting epithelialization with a thicker epithelial layer showing positive staining for keratin 5 and β-tubulin. β-tubulin expression was predominant in the iPSC-MSC group that also showed the presence of cilia-like structures. Importantly, the authors concluded that rather than replacement of the tracheal cartilage and regenerating the mucosal layer, hiPSC-MSCs, hiPSC-Chds, and hBECs are inducing remodeling through paracrine mechanisms involving cytokines, growth factors and ECM components.
Recent advancements in human ESC culture automation processes have allowed a larger-scale production of cartilage sheets. As an example, embryoid bodies derived from human ESCs were grown and differentiated on collagen with xeno-free chondrogenic media. After two months of automated culture, the resulting cell sheets were implanted subcutaneously in immunodeficient NOG mice. Another two months allowed the generation of mature fully differentiated cartilage sheets, and tests in preclinical models could prove promising [144].
Thus far, studies have shown that while promising, the use of iPSCs for cartilage regeneration is a highly complex and long process with several limitations. These include inefficiencies in the differentiation process leading to a variable number and size of embryoid bodies, composed of heterogeneous cell populations, and the presence of undesired cell lineages [145,146,147]. Given the existing challenges with cartilage regeneration, partial decellularization as an alternative has gained considerable attention. As such, tracheal grafts have been partially decellularized to remove only the epithelium, preserving chondrocytes [66]. Importantly, studies have shown that the cartilage, due to its dense matrix, is difficult to infiltrate and is thus immune-privileged and does not cause a significant immune response [148,149,150,151].

7. Recellularization Approaches for Epithelial Regeneration

The pseudostratified columnar epithelium of the proximal airways (trachea and main stem bronchi) is mainly composed of multiciliated, secretory cells with less represented populations of club cells, neuroendocrine cells (NECs), ionocytes, tuft cells, deuterosomal cells, and basal cells (BCs) (Figure 3) [152,153]. The proportions of goblet, secretory and basal cells vary along the proximal–distal axis. Airway goblet cells secrete mucus while ciliated cells, with their motile cilia lining the epithelial cells of the conductive airways, orchestrate mucociliary clearance [154]. Together with basal cells (the main progenitors of the airway epithelium), these cell populations are critical for the generation of a functional re-epithelialized tracheal graft.
Many groups have explored the potential of epithelial cells in accelerating tracheal regeneration by culturing these cells on the luminal surface of tracheal scaffolds ex vivo prior to transplantation [24,79,101]. The source of cells for recellularization is an important factor to consider. Primary tracheal epithelial cells are commonly used, as they have the ability to reconstitute the pseudostratified columnar epithelium, giving rise to the required goblet and ciliated cells (as in the native trachea) [21]. Additional primary epithelial cells have also been explored, such as those of the buccal mucosa and skin [18,119]. These studies have been summarized in Table 2. Despite promising proof-of-concept to date, primary epithelial cell sources are difficult to isolate and grow in culture, and they show high heterogeneity in differentiation capacity across donors with rapid changes in phenotype and function [155,156,157]. PSCs can self-renew unlimitedly and have the remarkable potential to differentiate into almost any cell type in the body. Therefore, they have been considered in developmental biology research, disease modeling, and regenerative medicine.

8. Use of PSCs for Epithelial Regeneration

Over the past few years, there has been significant interest in the application of PSCs for the repair and regeneration of the tracheal epithelium [24,25,40,77]. Several research groups have demonstrated the differentiation of PSCs into airway epithelial cells [39,40,107,158,159,160,161]. Differentiation protocols have recently been reviewed (see Varma et al. [162]). In brief, proximal lung epithelial cells are derived from PSCs via stepwise mimicry of the developmental signaling pathways beginning with differentiation to definitive endoderm (SOX17+ and FOXA2+), anteriorization to foregut endoderm (SOX2+FOXA2+) and subsequent ventralization to create NKX2-1+ lung progenitors. Lung progenitors obtain a proximal fate via the upregulation of SOX2, P63 and SCGB2A2, and they subsequently mature into multiciliated epithelium when exposed to air, which is typically via an air–liquid interface (ALI) culture system [162]. Here, we will summarize the current advances in generating tracheal grafts with the use of PSC-derived epithelial cells and their assessment in tracheal defect models (Figure 4).
The first use of PSCs in a tracheal scaffold was described by the Omori group [124]. The authors looked histologically and quantitatively at the propensity for teratoma formation after implantation into tracheal defects (1.5 mm × 2.5 mm) and abdominal subcutaneous tissue in rats. They employed mouse (iPS-MEF-Ng-20D-17) iPSCs in artificial tracheal scaffolds, consisting of collagenous sponge and polypropylene mesh. Specifically, undifferentiated mouse iPSCs suspended in collagen type I were introduced into artificial tracheas and cultured for six weeks under various media conditions (DMEM, DMEM + bone morphogenetic protein-2 (BMP-2), or chondrocyte differentiation medium). Histological evaluation showed the presence of undifferentiated cell colonies in all conditions after six weeks of ex vivo culture. To investigate site-dependent differences in teratoma formation, the cell-loaded artificial scaffolds were then transplanted into the cervical tissue around tracheal defects and in the abdominal subcutaneous tissue of nude rats. Four weeks after transplantation, teratoma formation was observed in both tracheal defect and subcutaneous areas with a higher number of teratomas in the cervical area in comparison to the abdominal subcutaneous tissue [103].
In later studies using the same model, this group reported that further differentiation of iPSCs via exposure to air-liquid interface (ALI) led to a significant reduction in the number of undifferentiated cells and reduced the risk of teratoma formation [77,125]. For these studies, iPSCs-derived embryoid bodies (EBs) were first cultured in differentiation medium for five days, which was followed by ALI culture for twenty-six days. In vitro examination over the ALI culture period showed the presence of conduit structures lined with epithelial cells as early as twelve days. At twenty-six days, ciliated-like structures appeared inside the conduits positive for β-tubulin IV (ciliated cell marker) and ZO-1 (tight junction formation marker). At the mRNA level, the authors observed increased expression of β-tubulin IV and Forkhead box protein J1 (FoxJ1) genes as well as reduced expression of Nanog (marker of undifferentiated PSC). ALI-conditioned EBs were then loaded onto their previously described artificial tracheal scaffold (12 EBs per scaffold) and transplanted into a tracheal defect in nude rats for 1 week. In vivo examination showed that the luminal side of the tracheal defect was covered with stratified epithelium and indicated the presence of ciliated structures on grafts expressing β-tubulin IV and ZO-1 [125]. While promising, the authors showed that the integration of iPSCs-derived tracheal epithelium into an artificial scaffold was challenging, and only 50% of nude rats used for the experiment showed iPSCs-derived tissues [77].
The authors, in a subsequent study, used tdTomato-labeled mouse iPSCs to distinguish undifferentiated iPSCs and iPSC-derived epithelial cells and better delineate the integration of transplanted mouse iPSCs [163]. Labeled iPSCs were subjected to EB formation and ALI culture, showing that tdTomato-labeled iPSC-derived cells co-expressed tdTomato and FoxJ1 after three weeks of expansion. Gene expression analysis confirmed the expression of tracheal epithelial markers including mucin 5AC (Muc5ac), keratin 5 (Krt5) and Tubulin beta-4a (Tubb4a) on day twenty-one. Labeled iPSC-derived airway cells (day twenty-six EBs) were loaded onto their collagen I/polypropylene mesh scaffolds and transplanted in nude rats. Results at one week post-transplantation showed tdTomato- and Krt5-positive cells in a section of the tracheal defects. Furthermore, cells derived from labeled iPSCs were clearly distinct from recipient basal cells, suggesting the potential for iPS-derived cells in reconstituting the epithelium [20]. The above-summarized studies all used mouse-derived pluripotent cells. With progress in directed differentiation protocols for epithelium derived from human PSCs, recent studies have also shown the application of human iPSC-derived epithelial cells.
The Omori group also investigated the feasibility of transplanting an airway patch loaded with human iPSCs (hiPSC)-derived multiciliated airway cells (hiPSC–MCACs) in their nude rat tracheal defect model [24]. They used the same artificial graft consisting of polypropylene mesh and collagen sponge. First, day forty-two proximal airway progenitor cells were cultured on collagen vitrigel membranes under ALI conditions to create a cell sheet. The internal side of an artificial trachea was covered by a hiPSC–MCACs sheet together with a collagen vitrigel membrane and implanted in a nude rat model of tracheal defect. In vivo analysis confirmed that the tracheal defect was covered with a thick layer of epithelia and presented hiPSC-derived ciliated cells for up to two weeks after transplantation. Importantly, the survival and stability of the hiPSC-derived cell sheets were observed with high efficiency (all seven animals at two weeks after transplantation) [24]. In order to ameliorate the cellular engraftment, the Omori group further investigate the optimal duration of hiPSC differentiation [164]. They tested thirty-eight, forty-five, and fifty-six days of differentiation from hiPSCs to induced airways epithelial cells (iAECs). The survival rate of iAECs differentiated from hiPSC at fifty-six days was greater than that in the forty-five day group, which was itself higher than that in the thirty-six-day group. They further analyzed the proportions of differentiated cell types within the tracheal patch two weeks after transplantation within tracheal defects in nude rats. Proportions of hiPSCs-derived differentiated ciliated cells, basal cells, club cells, and goblet cells are close to the ones found in a native healthy human tracheal epithelium [165]. Recently, this group challenged the use of nude rats as a suitable immunodeficient preclinical model and led a comparative study including X-linked severe combined immunodeficiency (X-SCID) rats. In both rat strains, tracheal defects were surgically created and replaced by a patch of collagen sponges and polypropylene mesh seeded with hiPSCs-derived AECs. Two weeks post-transplantation, cell engraftment was confirmed in both rat strains. However, all subtypes of CD3-positive immune cells were in significantly lower amounts in the X-SCID rats compared to the nude ones [166]. With a decreased immune reaction, X-SCID could represent a new preclinical option for a trachea-humanized rat model.
In our own studies, we developed a composite biomaterial of silk fibroin and collagen vitrigel membrane (SF-CVM), supporting an enhanced maturation of epithelial cells into ciliated cells and displaying desirable mechanical characteristic [167]. We investigated the preclinical application of SF-CVM-based tracheal graft loaded with human-induced pluripotent stem cell-derived airway epithelial cells in large animal airway defects. hiPSC-derived airway progenitors achieved differentiation into the mucociliary epithelium on an SF-CVM graft with physiological proportions of ciliated and goblet cells. They also proved good integration with host tracheal tissue when implanted into porcine airway defects, while there was no airway collapse. In addition, the majority (~80%) of the SF-CVM graft was covered with hiPSC-derived pseudostratified epithelium three days post-operatively, which reduces the inflammatory responses and granulation tissue formation [25]. Overall, the outcomes revealed a significant differentiation of ciliated cells from iPSCs compared to primary human tracheal epithelial cells, and they demonstrated the clinical potential of biological patches loaded with iPSC-derived cells to induce the re-epithelialization in vivo as well as their ability to maintain airway patency.
To the best of our knowledge, there is currently only one study investigating PSCs for tracheal regeneration in a full circumferential transplantation model [20]. Specifically, Zhou et al. compared the potential of a rat tracheal epithelial cell line (EGV-4T) and two mouse iPS cell lines for the recellularization of the luminal surface of a rat decellularized circumferential tracheal scaffold (5-rings long). The orthotopic transplantation of scaffolds recellularized with EGV-4T cells (n = 2) showed no granulation tissue, and recipient rats survived for thirty days. However, wheezing occurred immediately after transplantation, and the animals displayed a decrease in body weight. In addition, airway stenosis was observed with cell infiltration in the submucosa with no indication of ciliated cells. In the iPSCs group, GFP-labeled iPS cells pre-differentiated into a definitive endoderm (Sox17+) were used for the recellularization of decellularized rat tracheas. Recellularized tracheal scaffolds were orthotopically transplanted into nude rats. All rats survived at least four weeks post-transplantation but showed wheezing and dyspnea. Four out of five rats suffered airways stenosis caused by an extensive proliferation of contaminating undifferentiated iPSCs. While a ciliated epithelium was observed, there was no GFP expression, indicating that the cells originated from host tissue.
The regeneration and replacement of long segment circumferential defects using pluripotent stem cells has been challenging due to the limited availability of appropriate grafts for tracheal reconstruction, difficulties in whole trachea recellularization procedures, and challenges in deriving epithelial cells in the desired yield and purity. However, the summary of the studies showing the feasibility of using PSCs to generate smaller segments of transplantable tissue is promising [24,77,78,98,168,169]. We define smaller segments as non-circumferential biomaterial-based partial segments, composed of a natural or synthetic scaffold, on which a PSC-derived epithelium is cultured. These studies provide proof-of-concept data for future use in long segment tracheal transplantation applications. In certain cases, for example airway patches generated by our group [166], these smaller constructs have their own clinical utility. They are easier to fabricate and can be specifically used for the repair of damaged tissue requiring the replacement of the epithelium (Figure 4). Moreover, they can be the stepping stone to the generation of larger functional airway sheets which can, for instance, be applied to line the luminal surfaces of bioengineered long-segment circumferential tracheal grafts [21].

9. Challenges with iPSCs and Future Directions

While progress has clearly been achieved, the bioengineering of tracheal grafts has several inherent challenges that need continued efforts. These include the reconstitution of a functional cartilage and epithelium, biocompatibility and structural integrity, effective integration, and long-term stability following transplantation. The application of pluripotent stem cells for tracheal regeneration offers the potential of an unlimited source of cells from which a functional airway epithelium can be derived. Pluripotent-derived epithelial cells are advantageous in that they can be used as an autologous source, i.e., derived from a patient’s own somatic cells and hence non-immunogenic. They can also be genetically engineered to ‘escape’ the immune system, as per the recently generated hypo-immune pluripotent cell lines [170,171,172], and thus reduce the need for lifelong immunosuppressive therapies. There are, however, current limitations which hinder their clinical applicability. Current protocols for directed differentiation to epithelial cells are extremely long, labor-intensive and difficult to scale up [162,173,174,175]. It is also difficult to control the purity and yield of specific cell types [176,177,178]. For example, goblet cells are obtained at very low levels [179]. Research focusing on the optimization of directed differentiation protocols to reduce the time required to reach the desired products is necessary. Optimization efforts in other systems have included the use of biophysical cues, enhanced culture and the addition of small molecules to media formulations [180,181,182]. In the context of the airways, modifications involve the utilization of a 3D culture system (airway organoids) to produce induced basal cells (iBCs) from lung progenitors as well as the differentiation of iBCs into a pseudostratified airway epithelium through ALI culture [40,105]. In addition to challenges associated with their differentiation capability, several regulatory and manufacturing barriers must also be addressed. Major regulatory concerns include the risk of tumorigenicity, potential genomic instability during expansion and reprogramming, and the complexity of large-scale production under GMP conditions [183,184]. To reduce the heterogeneity and tumorigenicity in iPSC-derived cells, differentiated cells can be enriched via sorting strategies, and failsafe systems can eliminate aberrant or potentially tumorigenic cells in vivo [170,185,186]. Combined with optimized differentiation protocols and quality control, these approaches may improve the safety and reproducibility of iPSC-derived products and facilitated clinical translation [187]. Nevertheless, these challenges highlight the importance of developing universal pluripotent stem cells, offering off-the-shelf and immune-compatible tracheal graft.
In spite of the successful orthotopic transplantation of long-segment tracheal grafts in rodents [60,188], the surgery presents several challenges including grafts transplantation complexity, especially when involving a fully circumferential trachea. Depending on their anatomical constraints, this animal’s trachea may be too small and complicated to model accurately. On the other hand, anatomical and physiological differences between small animals and humans can affect the translation of the findings to human applications. Our prior research demonstrated that cells seeded on the graft facilitated the regeneration of the epithelium, reducing respiratory complications like stenosis and infection [25]. Nevertheless, the survival of animal models was assessed over a short period (days, weeks). Hence, future investigations should focus on examining the regenerative capabilities of tracheal grafts through long-term monitoring in animal models. Specifically, the assessment should prioritize the longevity and functionality of transplanted epithelial cells, particularly in relation to airway epithelium regeneration.
For the initial feasibility to use iPSCs, prior to processing to a larger scale involving non-economical large animals, a bioreactor offers a controlled and dynamic environment that replicates the physiological conditions necessary for the development and maturation of tissue constructs [18,19,189]. Depending on the specific tissue engineering approach, certain bioreactor designs may be more suitable. For trachea tissue engineering, complex bioreactors equipped with sensors and monitoring tools allow researchers to control various parameters, such as the temperature, pH, and oxygen levels, and assess the tissue development progress in real time. Bioreactors can enhance tracheal graft maturation by providing biochemical cues and mechanical stimulation and optimized nutrient flow for cartilage and epithelial cells proliferation and differentiation and develop biomechanically appropriate trachea constructs. An efficient bioreactor can ensure the uniform seeding and distribution of cells throughout the scaffold, resulting in a more homogeneous and functional tissue construct [19]. Focusing on the development and utilization of complex bioreactor systems, which allow mimicry of the dynamic microenvironments (i.e., breathing, and fluid flow), will be essential for supporting the generation of bioengineered long-segment tracheal constructs. Although this review focuses on epithelial regeneration using stem-cell-derived airway epithelial cells, vascularization remains a critical challenge in tracheal bioengineering. The lack of rapid blood supply in long-segment tracheal grafts can lead to graft ischemia, necrosis, and epithelial loss, which has shown graft failure in previous clinical attempts. Recent strategies such as the pre-vascularization of engineered constructs prior to implantation [190] and the controlled release of angiogenic growth factors (e.g., vascular endothelial growth factor (VEGF) [191], stromal cell-derived factor-1α (SDF-1α), transforming growth factor-β (TGF-β) [192] and endothelial-derived exosomes [193]) have shown the ability to promote rapid angiogenesis. Combining these approaches with epithelial and cartilage regeneration may improve the clinical translation of engineered tracheal grafts. Despite substantial progress, the successful clinical translation of stem cell-based tracheal regeneration will require continued advances in stem cell biology and the generation of a functional epithelium, adequate vascularization, biomaterial design, and long-term graft integration.

10. Conclusions

Despite challenges, trachea tissue engineering holds significant promise for revolutionizing the field of respiratory medicine and our ability to construct functional tracheal substitutes benefiting from pluripotent stem cell-derived cells. iPSCs can differentiate into epithelial cells, chondrocytes, and smooth muscle cells, thus allowing the regeneration of a functional epithelium using recipient-derived cells. In addition, recent advancements were made in emerging immune modulation technologies opening possibilities for the use of non-immunogenic cells, creating the potential for universal, off-the-shelf grafts with a reduced risk of immune rejection and improved long-term survival. Together, these technologies are paving the way for the eventual generation of off-the-shelf bioengineered tracheal grafts for effectively treating patients in need of tracheal transplants.

Author Contributions

Conceptualization, F.G. and G.K.; writing—original draft preparation, F.G. and G.K.; writing—review and editing, F.L.B., S.H. and G.K.; visualization, F.G. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Government of Canada’s New Frontiers in Research Fund (NFRF), NFRFT-2020-00787.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

All data relating to this manuscript is included within the article.

Conflicts of Interest

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

  1. Brand-Saberi, B.E.M.; Schafer, T. Trachea: Anatomy and physiology. Thorac. Surg. Clin. 2014, 24, 1–5. [Google Scholar] [CrossRef] [PubMed]
  2. Soleas, J.P.; Paz, A.; Marcus, P.; McGuigan, A.; Waddell, T.K. Engineering airway epithelium. J. Biomed. Biotechnol. 2012, 2012, 982971. [Google Scholar] [CrossRef]
  3. Polverino, M.; Polverino, F.; Fasolino, M.; Ando, F.; Alfieri, A.; De Blasio, F. Anatomy and neuro-pathophysiology of the cough reflex arc. Multidiscip. Respir. Med. 2012, 7, 5. [Google Scholar] [CrossRef]
  4. Cooper, J.D. Tracheal Injuries Complicating Prolonged Intubation and Tracheostomy. Thorac. Surg. Clin. 2018, 28, 139–144. [Google Scholar] [CrossRef]
  5. Prokakis, C.; Koletsis, E.N.; Dedeilias, P.; Fligou, F.; Filos, K.; Dougenis, D. Airway trauma: A review on epidemiology, mechanisms of injury, diagnosis and treatment. J. Cardiothorac. Surg. 2014, 9, 117. [Google Scholar] [CrossRef]
  6. Kalathur, M.; Baiguera, S.; Macchiarini, P. Translating tissue-engineered tracheal replacement from bench to bedside. Cell Mol. Life Sci. 2010, 67, 4185–4196. [Google Scholar] [CrossRef]
  7. Kapat, K.; Gondane, P.; Kumbhakarn, S.; Takle, S.; Sable, R. Challenges and Opportunities in Developing Tracheal Substitutes for the Recovery of Long-Segment Defects. Macromol. Biosci. 2024, 24, e2400054. [Google Scholar] [CrossRef]
  8. Dos Santos, A.C.; Machado Holzlsauer, G.; Ruiz Lucio de Lima Parra, J.P.; Querino Candelaria, R.A.; Santos da Silva, T.; da Silva Nunes Barreto, R.; Miglino, M.A. Organic and Synthetic Substitutes in Tracheal Reconstruction: A Scoping Review (2015–2025). Bioengineering 2025, 12, 704. [Google Scholar] [CrossRef]
  9. Kojima, K.; Bonassar, L.J.; Roy, A.K.; Vacanti, C.A.; Cortiella, J. Autologous tissue-engineered trachea with sheep nasal chondrocytes. J. Thorac. Cardiovasc. Surg. 2002, 123, 1177–1184. [Google Scholar] [CrossRef] [PubMed]
  10. Grimmer, J.F.; Gunnlaugsson, C.B.; Alsberg, E.; Murphy, H.S.; Kong, H.J.; Mooney, D.J.; Weatherly, R.A. Tracheal reconstruction using tissue-engineered cartilage. Arch. Otolaryngol.–Head Neck Surg. 2004, 130, 1191–1196. [Google Scholar] [CrossRef] [PubMed][Green Version]
  11. Dang, L.H.; Hung, S.H.; Tseng, Y.; Quang, L.X.; Le, N.T.N.; Fang, C.L.; Tseng, H. Partial Decellularized Scaffold Combined with Autologous Nasal Epithelial Cell Sheet for Tracheal Tissue Engineering. Int. J. Mol. Sci. 2021, 22, 10322. [Google Scholar] [CrossRef]
  12. Vacanti, C.A.; Paige, K.T.; Kim, W.S.; Sakata, J.; Upton, J.; Vacanti, J.P. Experimental tracheal replacement using tissue-engineered cartilage. J. Pediatr. Surg. 1994, 29, 201–204; discussion 204–205. [Google Scholar] [CrossRef]
  13. Kojima, K.; Bonassar, L.J.; Roy, A.K.; Mizuno, H.; Cortiella, J.; Vacanti, C.A. A composite tissue-engineered trachea using sheep nasal chondrocyte and epithelial cells. FASEB J. 2003, 17, 823–828, Erratum in FASEB J. 2014, 28, 5022. [Google Scholar] [CrossRef]
  14. Walles, T.; Giere, B.; Hofmann, M.; Schanz, J.; Hofmann, F.; Mertsching, H.; Macchiarini, P. Experimental generation of a tissue-engineered functional and vascularized trachea. J. Thorac. Cardiovasc. Surg. 2004, 128, 900–906. [Google Scholar] [CrossRef][Green Version]
  15. Elliott, M.J.; De Coppi, P.; Speggiorin, S.; Roebuck, D.; Butler, C.R.; Samuel, E.; Crowley, C.; McLaren, C.; Fierens, A.; Vondrys, D.; et al. Stem-cell-based, tissue engineered tracheal replacement in a child: A 2-year follow-up study. Lancet 2012, 380, 994–1000. [Google Scholar] [CrossRef]
  16. He, X.; Fu, W.; Zheng, J. Cell sources for trachea tissue engineering: Past, present and future. Regen. Med. 2012, 7, 851–863. [Google Scholar] [CrossRef]
  17. Maughan, E.F.; Hynds, R.E.; Proctor, T.J.; Janes, S.M.; Elliott, M.; Birchall, M.A.; Lowdell, M.W.; De Coppi, P. Autologous Cell Seeding in Tracheal Tissue Engineering. Curr. Stem Cell Rep. 2017, 3, 279–289. [Google Scholar] [CrossRef] [PubMed]
  18. Pai, A.C.; Lynch, T.J.; Ahlers, B.A.; Ievlev, V.; Engelhardt, J.F.; Parekh, K.R. A Novel Bioreactor for Reconstitution of the Epithelium and Submucosal Glands in Decellularized Ferret Tracheas. Cells 2022, 11, 1027. [Google Scholar] [CrossRef] [PubMed]
  19. Lee, H.; Marin-Araujo, A.E.; Aoki, F.G.; Haykal, S.; Waddell, T.K.; Amon, C.H.; Romero, D.A.; Karoubi, G. Computational fluid dynamics for enhanced tracheal bioreactor design and long-segment graft recellularization. Sci. Rep. 2021, 11, 1187. [Google Scholar] [CrossRef] [PubMed]
  20. Zhou, Q.; Ye, X.; Ran, Q.; Kitahara, A.; Matsumoto, Y.; Moriyama, M.; Ajioka, Y.; Saijo, Y. Trachea Engineering Using a Centrifugation Method and Mouse-Induced Pluripotent Stem Cells. Tissue Eng. Part C Methods 2018, 24, 524–533. [Google Scholar] [CrossRef]
  21. Kanzaki, M.; Yamato, M.; Hatakeyama, H.; Kohno, C.; Yang, J.; Umemoto, T.; Kikuchi, A.; Okano, T.; Onuki, T. Tissue engineered epithelial cell sheets for the creation of a bioartificial trachea. Tissue Eng. 2006, 12, 1275–1283. [Google Scholar] [CrossRef] [PubMed]
  22. de Sa Schiavo Matias, G.; Carreira, A.C.O.; Batista, V.F.; de Carvalho, H.J.C.; Miglino, M.A.; Fratini, P. In vivo biocompatibility analysis of the recellularized canine tracheal scaffolds with canine epithelial and endothelial progenitor cells. Bioengineered 2022, 13, 3551–3565. [Google Scholar] [CrossRef]
  23. Koo, J.P.; Kim, C.H.; Lee, J.G.; Kim, K.S.; Yoon, J.H. Airway reconstruction with carrier-free cell sheets composed of autologous nasal squamous epithelium. Laryngoscope 2007, 117, 1750–1755. [Google Scholar] [CrossRef]
  24. Okuyama, H.; Ohnishi, H.; Nakamura, R.; Yamashita, M.; Kishimoto, Y.; Tateya, I.; Suehiro, A.; Gotoh, S.; Takezawa, T.; Nakamura, T.; et al. Transplantation of multiciliated airway cells derived from human iPS cells using an artificial tracheal patch into rat trachea. J. Tissue Eng. Regen. Med. 2019, 13, 1019–1030. [Google Scholar] [CrossRef]
  25. Varma, R.; Marin-Araujo, A.E.; Rostami, S.; Waddell, T.K.; Karoubi, G.; Haykal, S. Short-Term Preclinical Application of Functional Human Induced Pluripotent Stem Cell-Derived Airway Epithelial Patches. Adv. Healthc. Mater. 2021, 10, e2100957. [Google Scholar] [CrossRef]
  26. Rai, N.; Singh, A.K.; Singh, S.K.; Gaurishankar, B.; Kamble, S.C.; Mishra, P.; Kotiya, D.; Barik, S.; Atri, N.; Gautam, V. Recent technological advancements in stem cell research for targeted therapeutics. Drug Deliv. Transl. Res. 2020, 10, 1147–1169. [Google Scholar] [CrossRef]
  27. Halevy, T.; Urbach, A. Comparing ESC and iPSC-Based Models for Human Genetic Disorders. J. Clin. Med. 2014, 3, 1146–1162. [Google Scholar] [CrossRef]
  28. Kim, J.B.; Zaehres, H.; Wu, G.; Gentile, L.; Ko, K.; Sebastiano, V.; Arauzo-Bravo, M.J.; Ruau, D.; Han, D.W.; Zenke, M.; et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 2008, 454, 646–650. [Google Scholar] [CrossRef]
  29. Li, Y.; Zhao, H.; Lan, F.; Lee, A.; Chen, L.; Lin, C.; Yao, Y.; Li, L. Generation of human-induced pluripotent stem cells from gut mesentery-derived cells by ectopic expression of OCT4/SOX2/NANOG. Cell. Reprogram. 2010, 12, 237–247. [Google Scholar] [CrossRef] [PubMed]
  30. Tomioka, I.; Maeda, T.; Shimada, H.; Kawai, K.; Okada, Y.; Igarashi, H.; Oiwa, R.; Iwasaki, T.; Aoki, M.; Kimura, T.; et al. Generating induced pluripotent stem cells from common marmoset (Callithrix jacchus) fetal liver cells using defined factors, including Lin28. Genes. Cells 2010, 15, 959–969. [Google Scholar] [CrossRef] [PubMed]
  31. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131, 861–872. [Google Scholar] [CrossRef]
  32. Singh, V.K.; Kalsan, M.; Kumar, N.; Saini, A.; Chandra, R. Induced pluripotent stem cells: Applications in regenerative medicine, disease modeling, and drug discovery. Front. Cell Dev. Biol. 2015, 3, 2. [Google Scholar] [CrossRef]
  33. Park, I.H.; Zhao, R.; West, J.A.; Yabuuchi, A.; Huo, H.; Ince, T.A.; Lerou, P.H.; Lensch, M.W.; Daley, G.Q. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451, 141–146. [Google Scholar] [CrossRef]
  34. Stadtfeld, M.; Nagaya, M.; Utikal, J.; Weir, G.; Hochedlinger, K. Induced pluripotent stem cells generated without viral integration. Science 2008, 322, 945–949. [Google Scholar] [CrossRef]
  35. Yu, J.; Hu, K.; Smuga-Otto, K.; Tian, S.; Stewart, R.; Slukvin, I.I.; Thomson, J.A. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009, 324, 797–801. [Google Scholar] [CrossRef] [PubMed]
  36. Firth, A.L.; Dargitz, C.T.; Qualls, S.J.; Menon, T.; Wright, R.; Singer, O.; Gage, F.H.; Khanna, A.; Verma, I.M. Generation of multiciliated cells in functional airway epithelia from human induced pluripotent stem cells. Proc. Natl. Acad. Sci. USA 2014, 111, E1723–E1730. [Google Scholar] [CrossRef]
  37. McCauley, K.B.; Hawkins, F.; Kotton, D.N. Derivation of Epithelial-Only Airway Organoids from Human Pluripotent Stem Cells. Curr. Protoc. Stem Cell Biol. 2018, 45, e51. [Google Scholar] [CrossRef]
  38. Suzuki, S.; Hawkins, F.J.; Barilla, C.; Beermann, M.L.; Kotton, D.N.; Davis, B.R. Differentiation of human pluripotent stem cells into functional airway basal stem cells. STAR Protoc. 2021, 2, 100683. [Google Scholar] [CrossRef]
  39. Wong, A.P.; Bear, C.E.; Chin, S.; Pasceri, P.; Thompson, T.O.; Huan, L.J.; Ratjen, F.; Ellis, J.; Rossant, J. Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein. Nat. Biotechnol. 2012, 30, 876–882. [Google Scholar] [CrossRef] [PubMed]
  40. Ma, L.; Thapa, B.R.; Le Suer, J.A.; Tilston-Lunel, A.; Herriges, M.J.; Berical, A.; Beermann, M.L.; Wang, F.; Bawa, P.S.; Kohn, A.; et al. Airway stem cell reconstitution by the transplantation of primary or pluripotent stem cell-derived basal cells. Cell Stem Cell 2023, 30, 1199–1216.e1197. [Google Scholar] [CrossRef] [PubMed]
  41. Abo, K.M.; Sainz de Aja, J.; Lindstrom-Vautrin, J.; Alysandratos, K.D.; Richards, A.; Garcia-de-Alba, C.; Huang, J.; Hix, O.T.; Werder, R.B.; Bullitt, E.; et al. Air-liquid interface culture promotes maturation and allows environmental exposure of pluripotent stem cell-derived alveolar epithelium. JCI Insight 2022, 7, e155589. [Google Scholar] [CrossRef]
  42. Madariaga, M.L.L.; Gaissert, H.A. Overview of malignant tracheal tumors. Ann. Cardiothorac. Surg. 2018, 7, 244–254. [Google Scholar] [CrossRef]
  43. Urdaneta, A.I.; Yu, J.B.; Wilson, L.D. Population based cancer registry analysis of primary tracheal carcinoma. Am. J. Clin. Oncol. 2011, 34, 32–37. [Google Scholar] [CrossRef]
  44. Esteller-More, E.; Ibanez, J.; Matino, E.; Adema, J.M.; Nolla, M.; Quer, I.M. Prognostic factors in laryngotracheal injury following intubation and/or tracheotomy in ICU patients. Eur. Arch. Otorhinolaryngol. 2005, 262, 880–883. [Google Scholar] [CrossRef] [PubMed]
  45. Sarper, A.; Ayten, A.; Eser, I.; Ozbudak, O.; Demircan, A. Tracheal stenosis aftertracheostomy or intubation: Review with special regard to cause and management. Tex. Heart Inst. J. 2005, 32, 154–158. [Google Scholar] [PubMed]
  46. Mattioli, F.; Marchioni, A.; Andreani, A.; Cappiello, G.; Fermi, M.; Presutti, L. Post-intubation tracheal stenosis in COVID-19 patients. Eur. Arch. Otorhinolaryngol. 2021, 278, 847–848. [Google Scholar] [CrossRef]
  47. Grillo, H.C. Tracheal replacement: A critical review. Ann. Thorac. Surg. 2002, 73, 1995–2004. [Google Scholar] [CrossRef]
  48. Ren, J.; Xu, Y.; Zhiyi, G.; Ren, T.; Ren, J.; Wang, K.; Luo, Y.; Zhu, M.; Tan, Q. Reconstruction of the trachea and carina: Surgical reconstruction, autologous tissue transplantation, allograft transplantation, and bioengineering. Thorac. Cancer 2022, 13, 284–295. [Google Scholar] [CrossRef]
  49. Honings, J.; Gaissert, H.A.; van der Heijden, H.F.; Verhagen, A.F.; Kaanders, J.H.; Marres, H.A. Clinical aspects and treatment of primary tracheal malignancies. Acta Oto-Laryngol. 2010, 130, 763–772. [Google Scholar] [CrossRef] [PubMed]
  50. Luo, J.S.; Cui, P.C.; Gao, P.F.; Nan, H.; Liu, Z.; Sun, Y.Z. Reconstruction of tracheal wall defect with a mesh patch of nickel-titanium shape-memory alloy. Ann. Otol. Rhinol. Laryngol. 2011, 120, 198–203. [Google Scholar] [CrossRef]
  51. Elliott, M.J.; Butler, C.R.; Varanou-Jenkins, A.; Partington, L.; Carvalho, C.; Samuel, E.; Crowley, C.; Lange, P.; Hamilton, N.J.; Hynds, R.E.; et al. Tracheal Replacement Therapy with a Stem Cell-Seeded Graft: Lessons from Compassionate Use Application of a GMP-Compliant Tissue-Engineered Medicine. Stem Cells Transl. Med. 2017, 6, 1458–1464. [Google Scholar] [CrossRef]
  52. Delaere, P.; Van Raemdonck, D.; Vranckx, J. Tracheal transplantation. Intensive Care Med. 2019, 45, 391–393. [Google Scholar] [CrossRef] [PubMed]
  53. Delaere, P.; Vranckx, J.; Verleden, G.; De Leyn, P.; Van Raemdonck, D.; Leuven Tracheal Transplant, G. Tracheal allotransplantation after withdrawal of immunosuppressive therapy. N. Engl. J. Med. 2010, 362, 138–145. [Google Scholar] [CrossRef] [PubMed]
  54. Vranckx, J.J.; Delaere, P. The current status and outlook of trachea transplantation. Curr. Opin. Organ. Transplant. 2020, 25, 601–608. [Google Scholar] [CrossRef] [PubMed]
  55. Fabre, D.; Kolb, F.; Fadel, E.; Mercier, O.; Mussot, S.; Le Chevalier, T.; Dartevelle, P. Successful tracheal replacement in humans using autologous tissues: An 8-year experience. Ann. Thorac. Surg. 2013, 96, 1146–1155. [Google Scholar] [CrossRef]
  56. Greaney, A.M.; Niklason, L.E. The History of Engineered Tracheal Replacements: Interpreting the Past and Guiding the Future. Tissue Eng. Part B Rev. 2021, 27, 341–352. [Google Scholar] [CrossRef]
  57. Chiang, T.; Pepper, V.; Best, C.; Onwuka, E.; Breuer, C.K. Clinical Translation of Tissue Engineered Trachea Grafts. Ann. Otol. Rhinol. Laryngol. 2016, 125, 873–885. [Google Scholar] [CrossRef]
  58. Loos, E.; Meulemans, J.; Vranckx, J.; Poorten, V.V.; Delaere, P. Tracheal Autotransplantation for Functional Reconstruction of Extended Hemilaryngectomy Defects: A Single-Center Experience in 30 Patients. Ann. Surg. Oncol. 2016, 23, 1674–1683. [Google Scholar] [CrossRef]
  59. Haykal, S.; Zhou, Y.; Marcus, P.; Salna, M.; Machuca, T.; Hofer, S.O.; Waddell, T.K. The effect of decellularization of tracheal allografts on leukocyte infiltration and of recellularization on regulatory T cell recruitment. Biomaterials 2013, 34, 5821–5832. [Google Scholar] [CrossRef]
  60. Liu, L.; Dharmadhikari, S.; Shontz, K.M.; Tan, Z.H.; Spector, B.M.; Stephens, B.; Bergman, M.; Manning, A.; Zhao, K.; Reynolds, S.D.; et al. Regeneration of partially decellularized tracheal scaffolds in a mouse model of orthotopic tracheal replacement. J. Tissue Eng. 2021, 12, 20417314211017417. [Google Scholar] [CrossRef]
  61. Hamilton, N.J.I.; Lee, D.D.H.; Gowers, K.H.C.; Butler, C.R.; Maughan, E.F.; Jevans, B.; Orr, J.C.; McCann, C.J.; Burns, A.J.; MacNeil, S.; et al. Bioengineered airway epithelial grafts with mucociliary function based on collagen IV- and laminin-containing extracellular matrix scaffolds. Eur. Respir. J. 2020, 55, 1901200. [Google Scholar] [CrossRef]
  62. Nakamura, R.; Katsuno, T.; Tateya, I.; Omori, K. Evaluation of Cilia Function in Rat Trachea Reconstructed Using Collagen Sponge Scaffold Seeded with Adipose Tissue-Derived Stem Cells. Anat. Rec. 2020, 303, 471–477. [Google Scholar] [CrossRef]
  63. Catoira, M.C.; Fusaro, L.; Di Francesco, D.; Ramella, M.; Boccafoschi, F. Overview of natural hydrogels for regenerative medicine applications. J. Mater. Sci. Mater. Med. 2019, 30, 115. [Google Scholar] [CrossRef]
  64. Chen, Z.; Zhong, N.; Wen, J.; Jia, M.; Guo, Y.; Shao, Z.; Zhao, X. Porous Three-Dimensional Silk Fibroin Scaffolds for Tracheal Epithelial Regeneration in Vitro and in Vivo. ACS Biomater. Sci. Eng. 2018, 4, 2977–2985. [Google Scholar] [CrossRef]
  65. Gilbert, T.W.; Sellaro, T.L.; Badylak, S.F. Decellularization of tissues and organs. Biomaterials 2006, 27, 3675–3683. [Google Scholar] [CrossRef]
  66. Aoki, F.G.; Varma, R.; Marin-Araujo, A.E.; Lee, H.; Soleas, J.P.; Li, A.H.; Soon, K.; Romero, D.; Moriya, H.T.; Haykal, S.; et al. De-epithelialization of porcine tracheal allografts as an approach for tracheal tissue engineering. Sci. Rep. 2019, 9, 12034. [Google Scholar] [CrossRef] [PubMed]
  67. Liu, L.; Dharmadhikari, S.; Spector, B.M.; Tan, Z.H.; Van Curen, C.E.; Agarwal, R.; Nyirjesy, S.; Shontz, K.; Sperber, S.A.; Breuer, C.K.; et al. Tissue-engineered composite tracheal grafts create mechanically stable and biocompatible airway replacements. J. Tissue Eng. 2022, 13, 20417314221108791. [Google Scholar] [CrossRef] [PubMed]
  68. Hong, P.; Bezuhly, M.; Graham, M.E.; Gratzer, P.F. Efficient decellularization of rabbit trachea to generate a tissue engineering scaffold biomatrix. Int. J. Pediatr. Otorhinolaryngol. 2018, 112, 67–74. [Google Scholar] [CrossRef]
  69. Gomes, K.T.; Prasad, P.R.; Sandhu, J.S.; Kumar, A.; Kumar, N.A.N.; Shridhar, N.B.; Bisht, B.; Paul, M.K. Decellularization techniques: Unveiling the blueprint for tracheal tissue engineering. Front. Bioeng. Biotechnol. 2025, 13, 1518905. [Google Scholar] [CrossRef]
  70. Taylor, D.A.; Sampaio, L.C.; Ferdous, Z.; Gobin, A.S.; Taite, L.J. Decellularized matrices in regenerative medicine. Acta Biomater. 2018, 74, 74–89. [Google Scholar] [CrossRef] [PubMed]
  71. Parmaksiz, M.; Dogan, A.; Odabas, S.; Elcin, A.E.; Elcin, Y.M. Clinical applications of decellularized extracellular matrices for tissue engineering and regenerative medicine. Biomed. Mater. 2016, 11, 022003. [Google Scholar] [CrossRef]
  72. Haykal, S.; Soleas, J.P.; Salna, M.; Hofer, S.O.; Waddell, T.K. Evaluation of the structural integrity and extracellular matrix components of tracheal allografts following cyclical decellularization techniques: Comparison of three protocols. Tissue Eng. Part C Methods 2012, 18, 614–623. [Google Scholar] [CrossRef]
  73. Hamilton, N.; Bullock, A.J.; Macneil, S.; Janes, S.M.; Birchall, M. Tissue engineering airway mucosa: A systematic review. Laryngoscope 2014, 124, 961–968. [Google Scholar] [CrossRef]
  74. Ohno, M.; Fuchimoto, Y.; Hsu, H.C.; Higuchi, M.; Komura, M.; Yamaoka, T.; Umezawa, A.; Enosawa, S.; Kuroda, T. Airway reconstruction using decellularized tracheal allografts in a porcine model. Pediatr. Surg. Int. 2017, 33, 1065–1071. [Google Scholar] [CrossRef]
  75. Ohno, M.; Fuchimoto, Y.; Higuchi, M.; Yamaoka, T.; Komura, M.; Umezawa, A.; Hsu, H.C.; Enosawa, S.; Kuroda, T. Long-term observation of airway reconstruction using decellularized tracheal allografts in micro-miniature pigs at growing stage. Regen. Ther. 2020, 15, 64–69. [Google Scholar] [CrossRef]
  76. Vigouroux, A.; Bonnin, Y.; Gendron, N.; Kellouche, S.; Agniel, R.; Bruneval, P.; Balvay, D.; Allain, J.M.; Chhun, S.; Kempf, H.; et al. Biointegration of a partially decellularized tracheal scaffold in a porcine model—Preliminary results. Sci. Rep. 2026; in press. [Google Scholar] [CrossRef]
  77. Ikeda, M.; Imaizumi, M.; Yoshie, S.; Nakamura, R.; Otsuki, K.; Murono, S.; Omori, K. Implantation of Induced Pluripotent Stem Cell-Derived Tracheal Epithelial Cells. Ann. Otol. Rhinol. Laryngol. 2017, 126, 517–524. [Google Scholar] [CrossRef] [PubMed]
  78. Jing, H.; Gao, B.; Gao, M.; Yin, H.; Mo, X.; Zhang, X.; Luo, K.; Feng, B.; Fu, W.; Wang, J.; et al. Restoring tracheal defects in a rabbit model with tissue engineered patches based on TGF-beta3-encapsulating electrospun poly(l-lactic acid-co-epsilon-caprolactone)/collagen scaffolds. Artif. Cells Nanomed. Biotechnol. 2018, 46, 985–995. [Google Scholar] [CrossRef] [PubMed]
  79. Park, J.H.; Yoon, J.K.; Lee, J.B.; Shin, Y.M.; Lee, K.W.; Bae, S.W.; Lee, J.; Yu, J.; Jung, C.R.; Youn, Y.N.; et al. Experimental Tracheal Replacement Using 3-dimensional Bioprinted Artificial Trachea with Autologous Epithelial Cells and Chondrocytes. Sci. Rep. 2019, 9, 2103. [Google Scholar] [CrossRef] [PubMed]
  80. Soriano, L.; Lemoine, M.; Cavanagh, B.; Johnston, A.; Khalid, T.; O’Brien, F.J.; O’Leary, C.; Cryan, S.A. Method for Targeted Cellular Seeding of Tubular Tissue-Engineered Scaffolds for Tracheal Regeneration Approaches. ACS Biomater. Sci. Eng. 2025, 11, 5293–5305. [Google Scholar] [CrossRef] [PubMed]
  81. Mir, S.M.; Chen, J.; Pinezich, M.R.; O’Neill, J.D.; Huang, S.X.L.; Vunjak-Novakovic, G.; Kim, J. Imaging-guided bioreactor for de-epithelialization and long-term cultivation of ex vivo rat trachea. Lab. Chip 2022, 22, 1018–1031. [Google Scholar] [CrossRef]
  82. Haykal, S.; Salna, M.; Zhou, Y.; Marcus, P.; Fatehi, M.; Frost, G.; Machuca, T.; Hofer, S.O.; Waddell, T.K. Double-chamber rotating bioreactor for dynamic perfusion cell seeding of large-segment tracheal allografts: Comparison to conventional static methods. Tissue Eng. Part C Methods 2014, 20, 681–692. [Google Scholar] [CrossRef] [PubMed]
  83. Peng, T.; Morrisey, E.E. Development of the pulmonary vasculature: Current understanding and concepts for the future. Pulm. Circ. 2013, 3, 176–178. [Google Scholar] [CrossRef]
  84. Gebb, S.A.; Shannon, J.M. Tissue interactions mediate early events in pulmonary vasculogenesis. Dev. Dyn. 2000, 217, 159–169. [Google Scholar] [CrossRef]
  85. Huckle, J.; Dootson, G.; Medcalf, N.; McTaggart, S.; Wright, E.; Carter, A.; Schreiber, R.; Kirby, B.; Dunkelman, N.; Stevenson, S.; et al. Differentiated chondrocytes for cartilage tissue engineering. Novartis Found. Symp. 2003, 249, 103–112; discussion 112–117, 170–174, 239–241. [Google Scholar] [CrossRef] [PubMed]
  86. Komura, M.; Komura, H.; Kanamori, Y.; Tanaka, Y.; Suzuki, K.; Sugiyama, M.; Nakahara, S.; Kawashima, H.; Hatanaka, A.; Hoshi, K.; et al. An animal model study for tissue-engineered trachea fabricated from a biodegradable scaffold using chondrocytes to augment repair of tracheal stenosis. J. Pediatr. Surg. 2008, 43, 2141–2146. [Google Scholar] [CrossRef]
  87. Komura, M.; Komura, H.; Tanaka, Y.; Kanamori, Y.; Sugiyama, M.; Nakahara, S.; Kawashima, H.; Suzuki, K.; Hoshi, K.; Iwanaka, T. Human tracheal chondrocytes as a cell source for augmenting stenotic tracheal segments: The first feasibility study in an in vivo culture system. Pediatr. Surg. Int. 2008, 24, 1117–1121. [Google Scholar] [CrossRef]
  88. Isogai, N.; Kusuhara, H.; Ikada, Y.; Ohtani, H.; Jacquet, R.; Hillyer, J.; Lowder, E.; Landis, W.J. Comparison of different chondrocytes for use in tissue engineering of cartilage model structures. Tissue Eng. 2006, 12, 691–703. [Google Scholar] [CrossRef]
  89. Gao, B.; Jing, H.; Gao, M.; Wang, S.; Fu, W.; Zhang, X.; He, X.; Zheng, J. Long-segmental tracheal reconstruction in rabbits with pedicled Tissue-engineered trachea based on a 3D-printed scaffold. Acta Biomater. 2019, 97, 177–186. [Google Scholar] [CrossRef]
  90. Zeng, T.; Yuan, P.; Liang, L.; Zhang, X.; Zhang, H.; Wu, W. Cartilaginous Extracellular Matrix Enriched with Human Gingival Mesenchymal Stem Cells Derived “Matrix Bound Extracellular Vesicles” Enabled Functional Reconstruction of Tracheal Defect. Adv. Sci. 2022, 9, e2102735. [Google Scholar] [CrossRef] [PubMed]
  91. Nomoto, Y.; Suzuki, T.; Tada, Y.; Kobayashi, K.; Miyake, M.; Hazama, A.; Wada, I.; Kanemaru, S.; Nakamura, T.; Omori, K. Tissue engineering for regeneration of the tracheal epithelium. Ann. Otol. Rhinol. Laryngol. 2006, 115, 501–506. [Google Scholar] [CrossRef]
  92. Pfenninger, C.; Leinhase, I.; Endres, M.; Rotter, N.; Loch, A.; Ringe, J.; Sittinger, M. Tracheal remodeling: Comparison of different composite cultures consisting of human respiratory epithelial cells and human chondrocytes. In Vitro Cell Dev. Biol. Anim. 2007, 43, 28–36. [Google Scholar] [CrossRef]
  93. Goto, Y.; Noguchi, Y.; Nomura, A.; Sakamoto, T.; Ishii, Y.; Bitoh, S.; Picton, C.; Fujita, Y.; Watanabe, T.; Hasegawa, S.; et al. In vitro reconstitution of the tracheal epithelium. Am. J. Respir. Cell Mol. Biol. 1999, 20, 312–318. [Google Scholar] [CrossRef]
  94. Fuchs, J.R.; Hannouche, D.; Terada, S.; Vacanti, J.P.; Fauza, D.O. Fetal tracheal augmentation with cartilage engineered from bone marrow-derived mesenchymal progenitor cells. J. Pediatr. Surg. 2003, 38, 984–987. [Google Scholar] [CrossRef]
  95. Yoon, I.S.; Chung, C.W.; Sung, J.H.; Cho, H.J.; Kim, J.S.; Shim, W.S.; Shim, C.K.; Chung, S.J.; Kim, D.D. Proliferation and chondrogenic differentiation of human adipose-derived mesenchymal stem cells in porous hyaluronic acid scaffold. J. Biosci. Bioeng. 2011, 112, 402–408. [Google Scholar] [CrossRef]
  96. Choi, Y.S.; Im, M.W.; Kim, C.S.; Lee, M.H.; Noh, S.E.; Lim, S.M.; Kim, S.L.; Cho, C.G.; Kim, D.I. Chondrogenic differentiation of human umbilical cord blood-derived multilineage progenitor cells in atelocollagen. Cytotherapy 2008, 10, 165–173. [Google Scholar] [CrossRef]
  97. Kolambkar, Y.M.; Peister, A.; Soker, S.; Atala, A.; Guldberg, R.E. Chondrogenic differentiation of amniotic fluid-derived stem cells. J. Mol. Histol. 2007, 38, 405–413. [Google Scholar] [CrossRef]
  98. Kobayashi, K.; Suzuki, T.; Nomoto, Y.; Tada, Y.; Miyake, M.; Hazama, A.; Wada, I.; Nakamura, T.; Omori, K. A tissue-engineered trachea derived from a framed collagen scaffold, gingival fibroblasts and adipose-derived stem cells. Biomaterials 2010, 31, 4855–4863. [Google Scholar] [CrossRef]
  99. Liu, J.; Nie, H.; Xu, Z.; Niu, X.; Guo, S.; Yin, J.; Guo, F.; Li, G.; Wang, Y.; Zhang, C. The effect of 3D nanofibrous scaffolds on the chondrogenesis of induced pluripotent stem cells and their application in restoration of cartilage defects. PLoS ONE 2014, 9, e111566. [Google Scholar] [CrossRef] [PubMed]
  100. Imaizumi, M.; Nomoto, Y.; Sugino, T.; Miyake, M.; Wada, I.; Nakamura, T.; Omori, K. Potential of induced pluripotent stem cells for the regeneration of the tracheal wall. Ann. Otol. Rhinol. Laryngol. 2010, 119, 697–703. [Google Scholar] [CrossRef] [PubMed]
  101. Kim, I.G.; Park, S.A.; Lee, S.H.; Choi, J.S.; Cho, H.; Lee, S.J.; Kwon, Y.W.; Kwon, S.K. Transplantation of a 3D-printed tracheal graft combined with iPS cell-derived MSCs and chondrocytes. Sci. Rep. 2020, 10, 4326. [Google Scholar] [CrossRef] [PubMed]
  102. Yoshimatsu, M.; Ohnishi, H.; Zhao, C.; Hayashi, Y.; Kuwata, F.; Kaba, S.; Okuyama, H.; Kawai, Y.; Hiwatashi, N.; Kishimoto, Y.; et al. In vivo regeneration of rat laryngeal cartilage with mesenchymal stem cells derived from human induced pluripotent stem cells via neural crest cells. Stem Cell Res. 2021, 52, 102233. [Google Scholar] [CrossRef]
  103. Imaizumi, M.; Nomoto, Y.; Sugino, T.; Otsuki, K.; Omori, K. Implantation site-dependent differences for tracheal regeneration with induced pluripotent stem cells (iPS cells). Acta Oto-Laryngol. 2013, 133, 405–411. [Google Scholar] [CrossRef]
  104. Liu, G.; David, B.T.; Trawczynski, M.; Fessler, R.G. Advances in Pluripotent Stem Cells: History, Mechanisms, Technologies, and Applications. Stem Cell Rev. Rep. 2020, 16, 3–32. [Google Scholar] [CrossRef] [PubMed]
  105. Hawkins, F.J.; Suzuki, S.; Beermann, M.L.; Barilla, C.; Wang, R.; Villacorta-Martin, C.; Berical, A.; Jean, J.C.; Le Suer, J.; Matte, T.; et al. Derivation of Airway Basal Stem Cells from Human Pluripotent Stem Cells. Cell Stem Cell 2021, 28, 79–95.e78. [Google Scholar] [CrossRef] [PubMed]
  106. Huang, S.X.; Islam, M.N.; O’Neill, J.; Hu, Z.; Yang, Y.G.; Chen, Y.W.; Mumau, M.; Green, M.D.; Vunjak-Novakovic, G.; Bhattacharya, J.; et al. Efficient generation of lung and airway epithelial cells from human pluripotent stem cells. Nat. Biotechnol. 2014, 32, 84–91. [Google Scholar] [CrossRef] [PubMed]
  107. McCauley, K.B.; Hawkins, F.; Serra, M.; Thomas, D.C.; Jacob, A.; Kotton, D.N. Efficient Derivation of Functional Human Airway Epithelium from Pluripotent Stem Cells via Temporal Regulation of Wnt Signaling. Cell Stem Cell 2017, 20, 844–857.e846. [Google Scholar] [CrossRef]
  108. Wang, R.; Hume, A.J.; Beermann, M.L.; Simone-Roach, C.; Lindstrom-Vautrin, J.; Le Suer, J.; Huang, J.; Olejnik, J.; Villacorta-Martin, C.; Bullitt, E.; et al. Human airway lineages derived from pluripotent stem cells reveal the epithelial responses to SARS-CoV-2 infection. Am. J. Physiol. Lung Cell Mol. Physiol. 2022, 322, L462–L478. [Google Scholar] [CrossRef]
  109. Wu, W.; Cheng, X.; Zhao, Y.; Chen, F.; Feng, X.; Mao, T. Tissue engineering of trachea-like cartilage grafts by using chondrocyte macroaggregate: Experimental study in rabbits. Artif. Organs 2007, 31, 826–834. [Google Scholar] [CrossRef]
  110. Tani, G.; Usui, N.; Kamiyama, M.; Oue, T.; Fukuzawa, M. In vitro construction of scaffold-free cylindrical cartilage using cell sheet-based tissue engineering. Pediatr. Surg. Int. 2010, 26, 179–185. [Google Scholar] [CrossRef]
  111. Henderson, J.H.; Welter, J.F.; Mansour, J.M.; Niyibizi, C.; Caplan, A.I.; Dennis, J.E. Cartilage tissue engineering for laryngotracheal reconstruction: Comparison of chondrocytes from three anatomic locations in the rabbit. Tissue Eng. 2007, 13, 843–853. [Google Scholar] [CrossRef]
  112. Kojima, K.; Bonassar, L.J.; Ignotz, R.A.; Syed, K.; Cortiella, J.; Vacanti, C.A. Comparison of tracheal and nasal chondrocytes for tissue engineering of the trachea. Ann. Thorac. Surg. 2003, 76, 1884–1888. [Google Scholar] [CrossRef]
  113. Ruszymah, B.H.; Chua, K.; Latif, M.A.; Hussein, F.N.; Saim, A.B. Formation of in vivo tissue engineered human hyaline cartilage in the shape of a trachea with internal support. Int. J. Pediatr. Otorhinolaryngol. 2005, 69, 1489–1495. [Google Scholar] [CrossRef]
  114. Giovannini, S.; Diaz-Romero, J.; Aigner, T.; Heini, P.; Mainil-Varlet, P.; Nesic, D. Micromass co-culture of human articular chondrocytes and human bone marrow mesenchymal stem cells to investigate stable neocartilage tissue formation in vitro. Eur. Cell Mater. 2010, 20, 245–259. [Google Scholar] [CrossRef]
  115. Mehlhorn, A.T.; Niemeyer, P.; Kaschte, K.; Muller, L.; Finkenzeller, G.; Hartl, D.; Sudkamp, N.P.; Schmal, H. Differential effects of BMP-2 and TGF-beta1 on chondrogenic differentiation of adipose derived stem cells. Cell Prolif. 2007, 40, 809–823. [Google Scholar] [CrossRef] [PubMed]
  116. Fuchs, J.R.; Hannouche, D.; Terada, S.; Zand, S.; Vacanti, J.P.; Fauza, D.O. Cartilage engineering from ovine umbilical cord blood mesenchymal progenitor cells. Stem Cells 2005, 23, 958–964. [Google Scholar] [CrossRef] [PubMed]
  117. Kunisaki, S.M.; Freedman, D.A.; Fauza, D.O. Fetal tracheal reconstruction with cartilaginous grafts engineered from mesenchymal amniocytes. J. Pediatr. Surg. 2006, 41, 675–682; discussion 675–682. [Google Scholar] [CrossRef]
  118. Kunisaki, S.M.; Fuchs, J.R.; Steigman, S.A.; Fauza, D.O. A comparative analysis of cartilage engineered from different perinatal mesenchymal progenitor cells. Tissue Eng. 2007, 13, 2633–2644. [Google Scholar] [CrossRef]
  119. Kim, J.H.; Kong, W.H.; Kim, J.G.; Kim, H.J.; Seo, S.W. Possibility of skin epithelial cell transdifferentiation in tracheal reconstruction. Artif. Organs 2011, 35, 122–130. [Google Scholar] [CrossRef] [PubMed]
  120. Zhang, X.; Jing, H.; Luo, K.; Shi, B.; Luo, Q.; Zhu, Z.; He, X.; Zheng, J. Exosomes from 3T3-J2 promote expansion of tracheal basal cells to facilitate rapid epithelization of 3D-printed double-layer tissue engineered trachea. Mater. Sci. Eng. C Mater. Biol. Appl. 2021, 129, 112371. [Google Scholar] [CrossRef]
  121. Coraux, C.; Nawrocki-Raby, B.; Hinnrasky, J.; Kileztky, C.; Gaillard, D.; Dani, C.; Puchelle, E. Embryonic stem cells generate airway epithelial tissue. Am. J. Respir. Cell Mol. Biol. 2005, 32, 87–92. [Google Scholar] [CrossRef]
  122. Van Vranken, B.E.; Romanska, H.M.; Polak, J.M.; Rippon, H.J.; Shannon, J.M.; Bishop, A.E. Coculture of embryonic stem cells with pulmonary mesenchyme: A microenvironment that promotes differentiation of pulmonary epithelium. Tissue Eng. 2005, 11, 1177–1187. [Google Scholar] [CrossRef]
  123. Wang, Y.; Wong, L.B.; Mao, H. Induction of ciliated cells from avian embryonic stem cells using three-dimensional matrix. Tissue Eng. Part C Methods 2010, 16, 929–936. [Google Scholar] [CrossRef] [PubMed]
  124. Imaizumi, M.; Nomoto, Y.; Sato, Y.; Sugino, T.; Miyake, M.; Wada, I.; Nakamura, T.; Omori, K. Evaluation of the use of induced pluripotent stem cells (iPSCs) for the regeneration of tracheal cartilage. Cell Transplant. 2013, 22, 341–353. [Google Scholar] [CrossRef] [PubMed]
  125. Ikeda, M.; Imaizumi, M.; Yoshie, S.; Otsuki, K.; Miyake, M.; Hazama, A.; Wada, I.; Omori, K. Regeneration of tracheal epithelium using mouse induced pluripotent stem cells. Acta Oto-Laryngol. 2016, 136, 373–378. [Google Scholar] [CrossRef]
  126. Hyde, D.M.; Hamid, Q.; Irvin, C.G. Anatomy, pathology, and physiology of the tracheobronchial tree: Emphasis on the distal airways. J. Allergy Clin. Immunol. 2009, 124, S72–S77. [Google Scholar] [CrossRef]
  127. Ko, J.Y.; Kim, K.I.; Park, S.; Im, G.I. In vitro chondrogenesis and in vivo repair of osteochondral defect with human induced pluripotent stem cells. Biomaterials 2014, 35, 3571–3581. [Google Scholar] [CrossRef]
  128. Homicz, M.R.; Schumacher, B.L.; Sah, R.L.; Watson, D. Effects of serial expansion of septal chondrocytes on tissue-engineered neocartilage composition. Otolaryngol. Head Neck Surg. 2002, 127, 398–408. [Google Scholar] [CrossRef]
  129. Coutu, D.L.; Mahfouz, W.; Loutochin, O.; Galipeau, J.; Corcos, J. Tissue engineering of rat bladder using marrow-derived mesenchymal stem cells and bladder acellular matrix. PLoS ONE 2014, 9, e111966. [Google Scholar] [CrossRef]
  130. Gao, M.; Yao, H.; Dong, Q.; Zhang, H.; Yang, Z.; Yang, Y.; Zhu, J.; Xu, M.; Xu, R. Tumourigenicity and Immunogenicity of Induced Neural Stem Cell Grafts Versus Induced Pluripotent Stem Cell Grafts in Syngeneic Mouse Brain. Sci. Rep. 2016, 6, 29955. [Google Scholar] [CrossRef]
  131. Caplan, A.I. Mesenchymal Stem Cells: Time to Change the Name! Stem Cells Transl. Med. 2017, 6, 1445–1451. [Google Scholar] [CrossRef] [PubMed]
  132. Musial-Wysocka, A.; Kot, M.; Majka, M. The Pros and Cons of Mesenchymal Stem Cell-Based Therapies. Cell Transplant. 2019, 28, 801–812. [Google Scholar] [CrossRef]
  133. Zhou, T.; Yuan, Z.; Weng, J.; Pei, D.; Du, X.; He, C.; Lai, P. Challenges and advances in clinical applications of mesenchymal stromal cells. J. Hematol. Oncol. 2021, 14, 24. [Google Scholar] [CrossRef]
  134. Pevsner-Fischer, M.; Levin, S.; Zipori, D. The origins of mesenchymal stromal cell heterogeneity. Stem Cell Rev. Rep. 2011, 7, 560–568. [Google Scholar] [CrossRef]
  135. Maleki, M.; Ghanbarvand, F.; Reza Behvarz, M.; Ejtemaei, M.; Ghadirkhomi, E. Comparison of mesenchymal stem cell markers in multiple human adult stem cells. Int. J. Stem Cells 2014, 7, 118–126. [Google Scholar] [CrossRef]
  136. Pelttari, K.; Winter, A.; Steck, E.; Goetzke, K.; Hennig, T.; Ochs, B.G.; Aigner, T.; Richter, W. Premature induction of hypertrophy during in vitro chondrogenesis of human mesenchymal stem cells correlates with calcification and vascular invasion after ectopic transplantation in SCID mice. Arthritis Rheum. 2006, 54, 3254–3266. [Google Scholar] [CrossRef]
  137. Teramura, T.; Onodera, Y.; Mihara, T.; Hosoi, Y.; Hamanishi, C.; Fukuda, K. Induction of mesenchymal progenitor cells with chondrogenic property from mouse-induced pluripotent stem cells. Cell. Reprogram. 2010, 12, 249–261. [Google Scholar] [CrossRef]
  138. Guzzo, R.M.; Gibson, J.; Xu, R.H.; Lee, F.Y.; Drissi, H. Efficient differentiation of human iPSC-derived mesenchymal stem cells to chondroprogenitor cells. J. Cell Biochem. 2013, 114, 480–490. [Google Scholar] [CrossRef]
  139. Wang, C.H.; Tsai, C.H.; Lin, T.L.; Liu, S.P. The Effects of Tgfb1 and Csf3 on Chondrogenic Differentiation of iPS Cells in 2D and 3D Culture Environment. Int. J. Mol. Sci. 2021, 22, 2978. [Google Scholar] [CrossRef]
  140. Alber, A.B.; Marquez, H.A.; Ma, L.; Kwong, G.; Thapa, B.R.; Villacorta-Martin, C.; Lindstrom-Vautrin, J.; Bawa, P.; Wang, F.; Luo, Y.; et al. Directed differentiation of mouse pluripotent stem cells into functional lung-specific mesenchyme. Nat. Commun. 2023, 14, 3488. [Google Scholar] [CrossRef]
  141. Lach, M.S.; Wroblewska, J.; Kulcenty, K.; Richter, M.; Trzeciak, T.; Suchorska, W.M. Chondrogenic Differentiation of Pluripotent Stem Cells under Controllable Serum-Free Conditions. Int. J. Mol. Sci. 2019, 20, 2711. [Google Scholar] [CrossRef]
  142. Suchorska, W.M.; Augustyniak, E.; Richter, M.; Trzeciak, T. Comparison of Four Protocols to Generate Chondrocyte-Like Cells from Human Induced Pluripotent Stem Cells (hiPSCs). Stem Cell Rev. Rep. 2017, 13, 299–308. [Google Scholar] [CrossRef]
  143. Mizuno, K.; Ohnishi, H.; Kishimoto, Y.; Kojima, T.; Fujimura, S.; Kawai, Y.; Kitano, M.; Ikeya, M.; Omori, K. Rat Tracheal Cartilage Regeneration Using Mesenchymal Stem Cells Derived From Human iPS Cells. Tissue Eng. Part A 2024, 31, 398–408. [Google Scholar] [CrossRef]
  144. Chen, J.; Kataoka, O.; Tsuchiya, K.; Oishi, Y.; Takao, A.; Huang, Y.C.; Komura, H.; Akiyama, S.; Itou, R.; Inui, M.; et al. Automated xeno-free chondrogenic differentiation from human embryonic stem cells: Enhancing efficiency and ensuring high-quality mass production. Regen. Ther. 2024, 26, 889–900. [Google Scholar] [CrossRef] [PubMed]
  145. Lach, M.S.; Rosochowicz, M.A.; Richter, M.; Jagiello, I.; Suchorska, W.M.; Trzeciak, T. The Induced Pluripotent Stem Cells in Articular Cartilage Regeneration and Disease Modelling: Are We Ready for Their Clinical Use? Cells 2022, 11, 529. [Google Scholar] [CrossRef]
  146. Skoracka, J.; Bajewska, K.; Kulawik, M.; Suchorska, W.; Kulcenty, K. Advances in cartilage tissue regeneration: A review of stem cell therapies, tissue engineering, biomaterials, and clinical trials. EXCLI J. 2024, 23, 1170–1182. [Google Scholar] [CrossRef] [PubMed]
  147. Murphy, C.; Mobasheri, A.; Tancos, Z.; Kobolak, J.; Dinnyes, A. The Potency of Induced Pluripotent Stem Cells in Cartilage Regeneration and Osteoarthritis Treatment. Adv. Exp. Med. Biol. 2018, 1079, 55–68. [Google Scholar] [CrossRef]
  148. Inui, A.; Iwakura, T.; Reddi, A.H. Human stem cells and articular cartilage regeneration. Cells 2012, 1, 994–1009. [Google Scholar] [CrossRef]
  149. Batioglu-Karaaltin, A.; Karaaltin, M.V.; Ovali, E.; Yigit, O.; Kongur, M.; Inan, O.; Bozkurt, E.; Cansiz, H. In vivo tissue-engineered allogenic trachea transplantation in rabbits: A preliminary report. Stem Cell Rev. Rep. 2015, 11, 347–356. [Google Scholar] [CrossRef]
  150. Revell, C.M.; Athanasiou, K.A. Success rates and immunologic responses of autogenic, allogenic, and xenogenic treatments to repair articular cartilage defects. Tissue Eng. Part B Rev. 2009, 15, 1–15. [Google Scholar] [CrossRef]
  151. Fujihara, Y.; Takato, T.; Hoshi, K. Immunological response to tissue-engineered cartilage derived from auricular chondrocytes and a PLLA scaffold in transgenic mice. Biomaterials 2010, 31, 1227–1234. [Google Scholar] [CrossRef]
  152. Zepp, J.A.; Morrisey, E.E. Cellular crosstalk in the development and regeneration of the respiratory system. Nat. Rev. Mol. Cell Biol. 2019, 20, 551–566. [Google Scholar] [CrossRef]
  153. Hogan, B.; Tata, P.R. Cellular organization and biology of the respiratory system. Nat. Cell Biol. 2019. [Google Scholar] [CrossRef]
  154. Petit, L.M.G.; Belgacemi, R.; Ancel, J.; Saber Cherif, L.; Polette, M.; Perotin, J.M.; Spassky, N.; Pilette, C.; Al Alam, D.; Deslee, G.; et al. Airway ciliated cells in adult lung homeostasis and COPD. Eur. Respir. Rev. 2023, 32, 230106. [Google Scholar] [CrossRef]
  155. Rayner, R.E.; Makena, P.; Prasad, G.L.; Cormet-Boyaka, E. Optimization of Normal Human Bronchial Epithelial (NHBE) Cell 3D Cultures for in vitro Lung Model Studies. Sci. Rep. 2019, 9, 500. [Google Scholar] [CrossRef]
  156. Ghosh, M.; Ahmad, S.; Jian, A.; Li, B.; Smith, R.W.; Helm, K.M.; Seibold, M.A.; Groshong, S.D.; White, C.W.; Reynolds, S.D. Human tracheobronchial basal cells. Normal versus remodeling/repairing phenotypes in vivo and in vitro. Am. J. Respir. Cell Mol. Biol. 2013, 49, 1127–1134. [Google Scholar] [CrossRef]
  157. Van de Laar, E.; Clifford, M.; Hasenoeder, S.; Kim, B.R.; Wang, D.; Lee, S.; Paterson, J.; Vu, N.M.; Waddell, T.K.; Keshavjee, S.; et al. Cell surface marker profiling of human tracheal basal cells reveals distinct subpopulations, identifies MST1/MSP as a mitogenic signal, and identifies new biomarkers for lung squamous cell carcinomas. Respir. Res. 2014, 15, 160. [Google Scholar] [CrossRef][Green Version]
  158. Tada, T.; Ohnishi, H.; Yamamoto, N.; Kuwata, F.; Hayashi, Y.; Okuyama, H.; Morino, T.; Kasai, Y.; Kojima, H.; Omori, K. Transplantation of a human induced pluripotent stem cell-derived airway epithelial cell sheet into the middle ear of rats. Regen. Ther. 2022, 19, 77–87. [Google Scholar] [CrossRef]
  159. Rodrigues Toste de Carvalho, A.L.; Liu, H.Y.; Chen, Y.W.; Porotto, M.; Moscona, A.; Snoeck, H.W. The in vitro multilineage differentiation and maturation of lung and airway cells from human pluripotent stem cell-derived lung progenitors in 3D. Nat. Protoc. 2021, 16, 1802–1829. [Google Scholar] [CrossRef]
  160. Berical, A.C.; Kiyokawa, H.; Beermann, M.L.; Wallman, D.; Cherfane, G.; Dunphy, V.; Pan, J.; Tilston-Lunel, A.; Varelas, X.; Horani, A.; et al. Airway Disease Modeling with Gene-Edited Human Basal Cell Transplantation. Am. J. Respir. Crit. Care Med. 2025, 211, 131–134. [Google Scholar] [CrossRef]
  161. Demchenko, A.; Kondrateva, E.; Tabakov, V.; Efremova, A.; Salikhova, D.; Bukharova, T.; Goldshtein, D.; Balyasin, M.; Bulatenko, N.; Amelina, E.; et al. Airway and Lung Organoids from Human-Induced Pluripotent Stem Cells Can Be Used to Assess CFTR Conductance. Int. J. Mol. Sci. 2023, 24, 6293. [Google Scholar] [CrossRef]
  162. Varma, R.; Soleas, J.P.; Waddell, T.K.; Karoubi, G.; McGuigan, A.P. Current strategies and opportunities to manufacture cells for modeling human lungs. Adv. Drug Deliv. Rev. 2020, 161–162, 90–109. [Google Scholar] [CrossRef] [PubMed]
  163. Yoshie, S.; Ikeda, M.; Imaizumi, M.; Otsuki, K.; Nomoto, Y.; Wada, I.; Omori, K. Visualization of mouse induced pluripotent stem cells for evaluation of tracheal regeneration. Acta Oto-Laryngol. 2015, 135, 395–401. [Google Scholar] [CrossRef]
  164. Mizuno, K.; Ohnishi, H.; Kishimoto, Y.; Okuyama, H.; Kawai, Y.; Kitano, M.; Hayashi, Y.; Omori, K. Transplantation of Human Induced Pluripotent Stem Cell-Derived Airway Epithelia at Different Induction Stages into Nude Rat. Cell. Reprogram. 2024, 26, 156–163. [Google Scholar] [CrossRef] [PubMed]
  165. Kitano, M.; Hayashi, Y.; Ohnishi, H.; Okuyama, H.; Yoshimatsu, M.; Mizuno, K.; Kuwata, F.; Tada, T.; Kishimoto, Y.; Morita, S.; et al. Changes in the Proportion of Each Cell Type After hiPSC-Derived Airway Epithelia Transplantation. Cell Transplant. 2024, 33, 9636897241228026. [Google Scholar] [CrossRef] [PubMed]
  166. Hayashi, Y.; Ohnishi, H.; Kitano, M.; Kishimoto, Y.; Takezawa, T.; Okuyama, H.; Yoshimatsu, M.; Kuwata, F.; Tada, T.; Mizuno, K.; et al. Comparative Study of Immunodeficient Rat Strains in Engraftment of Human-Induced Pluripotent Stem Cell-Derived Airway Epithelia. Tissue Eng. Part A 2024, 30, 144–153. [Google Scholar] [CrossRef]
  167. Varma, R.; Aoki, F.G.; Soon, K.; Karoubi, G.; Waddell, T.K. Optimal biomaterials for tracheal epithelial grafts: An in vitro systematic comparative analysis. Acta Biomater. 2018, 81, 146–157. [Google Scholar] [CrossRef]
  168. Nomoto, Y.; Kobayashi, K.; Tada, Y.; Wada, I.; Nakamura, T.; Omori, K. Effect of fibroblasts on epithelial regeneration on the surface of a bioengineered trachea. Ann. Otol. Rhinol. Laryngol. 2008, 117, 59–64. [Google Scholar] [CrossRef]
  169. Sun, F.; Lu, Y.; Wang, Z.; Zhang, B.; Shen, Z.; Yuan, L.; Wu, C.; Wu, Q.; Yang, W.; Zhang, G.; et al. Directly construct microvascularization of tissue engineering trachea in orthotopic transplantation. Mater. Sci. Eng. C Mater. Biol. Appl. 2021, 128, 112201. [Google Scholar] [CrossRef]
  170. Harding, J.; Vintersten-Nagy, K.; Yang, H.; Tang, J.K.; Shutova, M.; Jong, E.D.; Lee, J.H.; Massumi, M.; Oussenko, T.; Izadifar, Z.; et al. Immune-privileged tissues formed from immunologically cloaked mouse embryonic stem cells survive long term in allogeneic hosts. Nat. Biomed. Eng. 2024, 8, 427–442. [Google Scholar] [CrossRef]
  171. Pavan, C.; Davidson, K.C.; Payne, N.; Frausin, S.; Hunt, C.P.J.; Moriarty, N.; Berrocal Rubio, M.A.; Elahi, Z.; Quattrocchi, A.T.; Abu-Bonsrah, K.D.; et al. A cloaked human stem-cell-derived neural graft capable of functional integration and immune evasion in rodent models. Cell Stem Cell 2025, 32, 710–726 e718. [Google Scholar] [CrossRef]
  172. Kim, J.; Nam, Y.; Jeon, D.; Choi, Y.; Choi, S.; Hong, C.P.; Kim, S.; Jung, H.; Park, N.; Sohn, Y.; et al. Generation of hypoimmunogenic universal iPS cells through HLA-type gene knockout. Exp. Mol. Med. 2025, 57, 686–699. [Google Scholar] [CrossRef]
  173. Hawkins, F.; Kotton, D.N. Embryonic and induced pluripotent stem cells for lung regeneration. Ann. Am. Thorac. Soc. 2015, 12, S50–S53. [Google Scholar] [CrossRef] [PubMed]
  174. Jacob, A.; Vedaie, M.; Roberts, D.A.; Thomas, D.C.; Villacorta-Martin, C.; Alysandratos, K.D.; Hawkins, F.; Kotton, D.N. Derivation of self-renewing lung alveolar epithelial type II cells from human pluripotent stem cells. Nat. Protoc. 2019, 14, 3303–3332. [Google Scholar] [CrossRef]
  175. Gadalla, D.; Kennedy, M.M.; Lott, D.G. Advances and Challenges in Tracheal Epithelium Regeneration: Insights into Tissue Engineering Approaches. Cells Tissues Organs 2026, 215, 56–80. [Google Scholar] [CrossRef]
  176. Liao, C.M.; Mukherjee, S.; Tiyaboonchai, A.; Maguire, J.A.; Cardenas-Diaz, F.L.; French, D.L.; Gadue, P. GATA6 suppression enhances lung specification from human pluripotent stem cells. J. Clin. Investig. 2018, 128, 2944–2950. [Google Scholar] [CrossRef]
  177. Mitchell, A.; Drinnan, C.T.; Jensen, T.; Finck, C. Production of high purity alveolar-like cells from iPSCs through depletion of uncommitted cells after AFE induction. Differentiation 2017, 96, 62–69. [Google Scholar] [CrossRef] [PubMed]
  178. Hawkins, F.; Kramer, P.; Jacob, A.; Driver, I.; Thomas, D.C.; McCauley, K.B.; Skvir, N.; Crane, A.M.; Kurmann, A.A.; Hollenberg, A.N.; et al. Prospective isolation of NKX2-1-expressing human lung progenitors derived from pluripotent stem cells. J. Clin. Investig. 2017, 127, 2277–2294. [Google Scholar] [CrossRef] [PubMed]
  179. Nomi, K.; Hayashi, R.; Ishikawa, Y.; Kobayashi, Y.; Katayama, T.; Quantock, A.J.; Nishida, K. Generation of functional conjunctival epithelium, including goblet cells, from human iPSCs. Cell Rep. 2021, 34, 108715. [Google Scholar] [CrossRef]
  180. Choi, B.; Kim, D.; Han, I.; Lee, S.H. Microenvironmental Regulation of Stem Cell Behavior Through Biochemical and Biophysical Stimulation. Adv. Exp. Med. Biol. 2018, 1064, 147–160. [Google Scholar] [CrossRef]
  181. Jain, I.; Berg, I.C.; Acharya, A.; Blaauw, M.; Gosstola, N.; Perez-Pinera, P.; Underhill, G.H. Delineating cooperative effects of Notch and biomechanical signals on patterned liver differentiation. Commun. Biol. 2022, 5, 1073. [Google Scholar] [CrossRef]
  182. Suzuki, D.; Pinto, F.; Senoo, M. Inhibition of TGF-beta signaling supports high proliferative potential of diverse p63(+) mouse epithelial progenitor cells in vitro. Sci. Rep. 2017, 7, 6089. [Google Scholar] [CrossRef]
  183. Dhaiban, S.; Chandran, S.; Noshi, M.; Sajini, A.A. Clinical translation of human iPSC technologies: Advances, safety concerns, and future directions. Front. Cell Dev. Biol. 2025, 13, 1627149. [Google Scholar] [CrossRef]
  184. Neofytou, E.; O’Brien, C.G.; Couture, L.A.; Wu, J.C. Hurdles to clinical translation of human induced pluripotent stem cells. J. Clin. Investig. 2015, 125, 2551–2557. [Google Scholar] [CrossRef] [PubMed]
  185. Zhong, C.; Liu, M.; Pan, X.; Zhu, H. Tumorigenicity risk of iPSCs in vivo: Nip it in the bud. Precis. Clin. Med. 2022, 5, pbac004. [Google Scholar] [CrossRef]
  186. Martin, R.M.; Fowler, J.L.; Cromer, M.K.; Lesch, B.J.; Ponce, E.; Uchida, N.; Nishimura, T.; Porteus, M.H.; Loh, K.M. Improving the safety of human pluripotent stem cell therapies using genome-edited orthogonal safeguards. Nat. Commun. 2020, 11, 2713. [Google Scholar] [CrossRef]
  187. Xia, L.; Qin, J.; Ye, S. Addressing the challenges of immunogenicity, heterogeneity and tumorigenicity in the clinical translation of human embryonic stem cells. Stem Cell Res. Ther. 2025, 16, 694. [Google Scholar] [CrossRef]
  188. Zeng, N.; Chen, Y.; Wu, Y.; Zang, M.; Largo, R.D.; Chang, E.I.; Schaverien, M.V.; Yu, P.; Zhang, Q. Pre-epithelialized cryopreserved tracheal allograft for neo-trachea flap engineering. Front. Bioeng. Biotechnol. 2023, 11, 1196521. [Google Scholar] [CrossRef] [PubMed]
  189. Asnaghi, M.A.; Jungebluth, P.; Raimondi, M.T.; Dickinson, S.C.; Rees, L.E.; Go, T.; Cogan, T.A.; Dodson, A.; Parnigotto, P.P.; Hollander, A.P.; et al. A double-chamber rotating bioreactor for the development of tissue-engineered hollow organs: From concept to clinical trial. Biomaterials 2009, 30, 5260–5269. [Google Scholar] [CrossRef]
  190. Nyirjesy, S.C.; Yu, J.; Dharmadhikari, S.; Liu, L.; Bergman, M.; Tan, Z.H.; VanKoevering, K.K.; Chiang, T. Successful Early Neovascularization in Composite Tracheal Grafts. Otolaryngol. Head Neck Surg. 2023, 169, 1035–1040. [Google Scholar] [CrossRef]
  191. Zhang, B.; Liu, J.; Lu, Y.; Sun, F.; Ye, J.; Wu, Q.; Zheng, Z.; Lu, S.; Zhu, X.; Hu, H.; et al. A novel bilayer composite artificial trachea with in situ vascularization function for tracheal defect reconstruction. Chem. Eng. J. 2026, 534, 174405. [Google Scholar] [CrossRef]
  192. Liu, Y.; Zheng, K.; Meng, Z.; Wang, L.; Liu, X.; Guo, B.; He, J.; Tang, X.; Liu, M.; Ma, N.; et al. A cell-free tissue-engineered tracheal substitute with sequential cytokine release maintained airway opening in a rabbit tracheal full circumferential defect model. Biomaterials 2023, 300, 122208. [Google Scholar] [CrossRef] [PubMed]
  193. Shen, Z.; Sun, F.; Shan, Y.; Lu, Y.; Wu, C.; Zhang, B.; Wu, Q.; Yuan, L.; Zhu, J.; Wang, Q.; et al. Construction of a novel cell-free tracheal scaffold promoting vascularization for repairing tracheal defects. Mater. Today Bio 2023, 23, 100841. [Google Scholar] [CrossRef] [PubMed]
Ijms 27 02891 g001
Figure 1. Bioengineering approaches in tracheal tissue engineering. Schematic illustration showing a general overview of tracheal tissue engineering highlighting the use of decellularized tissues. Decellularized tracheal grafts have been recellularized with various cell types including autologous cells derived from the patient’s own tissues, allogeneic cells from donors, and iPSC-derived cells to construct functional tracheal grafts.
Figure 1. Bioengineering approaches in tracheal tissue engineering. Schematic illustration showing a general overview of tracheal tissue engineering highlighting the use of decellularized tissues. Decellularized tracheal grafts have been recellularized with various cell types including autologous cells derived from the patient’s own tissues, allogeneic cells from donors, and iPSC-derived cells to construct functional tracheal grafts.
Ijms 27 02891 g001
Ijms 27 02891 g002
Figure 2. Strategies for repairing airway cartilage. (Top): Mouse iPSC-derived chondrocytes seeded on a polypropylene mesh with a collagenous sponge formed cartilage-like tissue after implantation in nude rats [100,124]. (Bottom): A bi-layered PCL scaffold seeded with iPSC-derived mesenchymal stem cells (MSCs), chondrocytes, and human bronchial epithelial cells (hBECs) promoted neocartilage formation and epithelialization in a rabbit model [101]. Created with BioRender.com (accessed on 5 February 2026).
Figure 2. Strategies for repairing airway cartilage. (Top): Mouse iPSC-derived chondrocytes seeded on a polypropylene mesh with a collagenous sponge formed cartilage-like tissue after implantation in nude rats [100,124]. (Bottom): A bi-layered PCL scaffold seeded with iPSC-derived mesenchymal stem cells (MSCs), chondrocytes, and human bronchial epithelial cells (hBECs) promoted neocartilage formation and epithelialization in a rabbit model [101]. Created with BioRender.com (accessed on 5 February 2026).
Ijms 27 02891 g002
Ijms 27 02891 g003
Figure 3. The cellular composition of tracheal epithelium. The cartilaginous airway is covered with a pseudostratified epithelium consisting of ciliated, secretory, basal and neuroendocrine cells. The proximal trachea is characterized by submucosal glands (SMGs) located between cartilage rings. The SMG ducts contain a population of stem cells that act as a stem cell reservoir for the tracheal epithelium. Created with BioRender.com (accessed on 5 February 2026).
Figure 3. The cellular composition of tracheal epithelium. The cartilaginous airway is covered with a pseudostratified epithelium consisting of ciliated, secretory, basal and neuroendocrine cells. The proximal trachea is characterized by submucosal glands (SMGs) located between cartilage rings. The SMG ducts contain a population of stem cells that act as a stem cell reservoir for the tracheal epithelium. Created with BioRender.com (accessed on 5 February 2026).
Ijms 27 02891 g003
Ijms 27 02891 g004
Figure 4. Strategies for repairing airway epithelium. This schematic summarizes recent strategies for tracheal epithelial regeneration using stem-cell-derived or primary airway epithelial cells combined with natural or synthetic scaffolds. (A) A sheet of epithelial cells generated from primary airway epithelial cells was combined with a de-epithelialized trachea and then transplanted into rabbits with a 0.7 × 0.7 cm tracheal defect [11]. (B) Human-induced pluripotent stem cell (hiPSC)-derived lung progenitors were combined with a composite biomaterial of silk fibroin and collagen vitrigel membrane (SF-CVM); then, they were followed with a preclinical application of graft in large animals with a 4 × 2 cm tracheal defect [25]. (C) An airway patch loaded with hiPSC-derived multiciliated airway cells (hiPSC–MCACs) was transplanted into nude rats with a 1.5 × 2.5 mm tracheal defect [24]. (D) Mouse iPSC-derived airway cells (day28 EBs) were loaded onto collagen I/polypropylene mesh scaffolds and transplanted into a nude rat tracheal defect model [125]. (E) A mouse iPSC-derived definitive endoderm and rat tracheal epithelial cell line were used to recellularize decellularized circumferential tracheal scaffolds and transplanted into a nude rat tracheal defect model [20]. Images were generated based on the information provided in the papers. Created with BioRender.com (accessed on 6 February 2026).
Figure 4. Strategies for repairing airway epithelium. This schematic summarizes recent strategies for tracheal epithelial regeneration using stem-cell-derived or primary airway epithelial cells combined with natural or synthetic scaffolds. (A) A sheet of epithelial cells generated from primary airway epithelial cells was combined with a de-epithelialized trachea and then transplanted into rabbits with a 0.7 × 0.7 cm tracheal defect [11]. (B) Human-induced pluripotent stem cell (hiPSC)-derived lung progenitors were combined with a composite biomaterial of silk fibroin and collagen vitrigel membrane (SF-CVM); then, they were followed with a preclinical application of graft in large animals with a 4 × 2 cm tracheal defect [25]. (C) An airway patch loaded with hiPSC-derived multiciliated airway cells (hiPSC–MCACs) was transplanted into nude rats with a 1.5 × 2.5 mm tracheal defect [24]. (D) Mouse iPSC-derived airway cells (day28 EBs) were loaded onto collagen I/polypropylene mesh scaffolds and transplanted into a nude rat tracheal defect model [125]. (E) A mouse iPSC-derived definitive endoderm and rat tracheal epithelial cell line were used to recellularize decellularized circumferential tracheal scaffolds and transplanted into a nude rat tracheal defect model [20]. Images were generated based on the information provided in the papers. Created with BioRender.com (accessed on 6 February 2026).
Ijms 27 02891 g004
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ganji, F.; Le Billan, F.; Haykal, S.; Karoubi, G. Tracheal Regeneration: Recent Progress in the Application of Stem Cells in Tracheal Bioengineering. Int. J. Mol. Sci. 2026, 27, 2891. https://doi.org/10.3390/ijms27062891

AMA Style

Ganji F, Le Billan F, Haykal S, Karoubi G. Tracheal Regeneration: Recent Progress in the Application of Stem Cells in Tracheal Bioengineering. International Journal of Molecular Sciences. 2026; 27(6):2891. https://doi.org/10.3390/ijms27062891

Chicago/Turabian Style

Ganji, Fatemeh, Florian Le Billan, Siba Haykal, and Golnaz Karoubi. 2026. "Tracheal Regeneration: Recent Progress in the Application of Stem Cells in Tracheal Bioengineering" International Journal of Molecular Sciences 27, no. 6: 2891. https://doi.org/10.3390/ijms27062891

APA Style

Ganji, F., Le Billan, F., Haykal, S., & Karoubi, G. (2026). Tracheal Regeneration: Recent Progress in the Application of Stem Cells in Tracheal Bioengineering. International Journal of Molecular Sciences, 27(6), 2891. https://doi.org/10.3390/ijms27062891

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop